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Poster Presentations from the 2018 Maine Medical Center
Research Institute (MMCRI) Summer Student Research
Program
The following posters were presented as part of the 2018 MMCRI Summer Student Research Program.
This program offers undergraduates and medical students a unique opportunity to conduct research in
diverse clinical and biomedical science fields during the summer months. During the paid ten-week program,
students participate in mentored independent research projects either in our state-of-the-art research facility,
or working with physicians in a hospital setting to impact patient care or the outcome of treatment. Students
also attend lectures and workshops featuring topics including bioethics, animal use in biomedical science and
scientific presentation skills, and have the opportunity to attend presentations by guest scientists and MMCRI
faculty. All students give a final presentation, which in 2018 involved a three minute oral presentation called a
“Three Minute Thesis” as well as a scientific poster presentation. All authors have an affiliation with MMCRI,
unless otherwise noted.
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The Role of Lipid Metabolism in Multiple Myeloma
1Maine

DeSchiffart, Abigail1; Masarwi, Majdi1; Reagan, Michaela R.1,2,3
Medical Center Research Institute, 2Tufts University School of Medicine, 3University of Maine Graduate
School of Biomedical Science and Engineering
INTRODUCTION

RESULTS

•Multiple Myeloma (MM) is the second most common type of hematological cancer, formed from a series of
oncogenetic mutations to the plasma cells of the bone marrow (1).
•Initially patients respond well to chemotherapeutic treatment, but almost all eventually develop resistance to these
treatments and experience relapse.
•Myeloma thrives in the unique and complex bone marrow microenvironment. Also, within the bone marrow are bone
marrow adipocytes (BMA) that form bone marrow adipose tissue and account for 50-70% of the total bone marrow
volume. It is believed that BMAT provides a source of energy that aids in multiple myeloma cell metastasis (2).
•Fatty acid oxidation is the process by which cells convert long chain fatty acids into NADH, FADH2, and ATP in the
mitochondria.
•CPT1 is a transport enzyme in the outer mitochondrial membrane that transports long chain fatty acids into the inner
mitochondrial space. It is the first, yet rate limiting enzyme of the carnitine system and subsequently of fatty acid
oxidation (3).
•Etomoxir (Eto) is an pharmacological irreversible inhibitor of CPT1, effectively inhibiting fatty acid oxidation.
•In other cancers, such as breast and prostate cancer, inhibiting fatty acid oxidation with the use of etomoxir has been
proven to reduce cancer cell viability and proliferation.
•Recently etomoxir has been shown to have off target effects by inhibiting complex one of the electron transport chain
at high dosages (4).

2. In vitro Combination Treatment of Etomoxir and Bortezomib
Eto 0 µM

Eto 5µM

Eto 12.5µM

A OPM2: Etomoxir + Bortezomib

B MM1R: Etomoxir + Bortezomib

•In addition to a potential energy source, BMAT has been shown
to increase MM’s resistance to chemotherapeutic treatments (5).
•We are examining the effect of etomoxir on different MM cell
lines and if it increases MM sensitivity to chemotherapeutic drugs.

Objective and Aims: An in vitro investigation at the effects
of inhibiting CPT1 on MM cells and to design a drug
combination treatment that effectively reduces MM cell
viability.
Figure 1 : Melone et al. Cell Death & Disease 2018. The carnitine system processes
Hypothesis: Inhibiting fatty acid oxidation in multiple
long-chain fatty acids across the mitochondrial membrane, forming acylcarnitine.
myeloma cell lines will reduce cell viability and increase Acylcarnitine then enters the mitochondrial matrix via carnitine-acylcarnitine
translocase (CACT) to undergo β-oxidation. Once in the form of Acetyl CoA, the
their sensitivity to other chemotherapeutic drugs.
fatty acid enters the Krebs cycle to produce ATP. (6)

METHODS
Cell Culture: MM1S (gfp+/luc+), MM1R (gfp+/luc+), and OPM2 (mcherry/luc+) were seeded at various densities into
clear and white 96 well plates.
Drug administration: Etomoxir (CPT1 inhibitor), Bortezomib (proteasome inhibitor), and Dexamethasone
(corticosteroid that reduces inflammation) were added at various doses 24 hours after the cells were seeded.
Bortezomib and dexamethasone are common pharmacological anti-myeloma treatments.
Cell Number: Bioluminescent imaging (BLI) was used to quantify cell viability. Luciferin (10 µL) was added to each
well and incubated for 15 minutes before reading with Glomax® Microplate Reader. BLI was read after 24, 48, 72,
and 96 hours after the drugs were administered to the cells.

1. In Vitro Measurement of Cell Viability using Bioluminescent Imaging for MM Cells
Treated with Etomoxir

Cell viability of (A) OPM2 and (B) MM1R cells treated with etomoxir (eto) at 0 µM, 5 µM or 12.5 µM, in addition to various
doses of bortezomib (bort), specifically 0 nM, 0.25 nM, 1 nM, or 5 nM. Bioluminescence was used to measure tumor cell
number and was read 72 hours after the drugs were administered. OPM2 cells were seeded at 20,000 cells/well in 96well plates. *, p<0.05; **, p<0.01.

3. In vitro Combination Treatment of Etomoxir and Dexamethasone Co-Cultured with
MSCs
MM1S cells were directly co-cultured with mouse
mesenchymal stem cells (mMSCs) for 24 hours
before etomoxir (5µM) and dexamethasone
(0.5µM) were administered . The mMSCs were
seeded at a cell density of 7500 cells/well. The
MM1S cells were seeded at a cell density of 5000
cells/well. Statistical analysis was done using one
way ANOVA test. *, p<0.05; ****p< 0.0001.

Bioluminescence read 24 hours after 500 µM etomoxir was added to the
cells. MM1S cultured at a cell density of 40,000 cells/well.
****, p< 0.0001

CONCLUSIONS
A

MM1S 24 hour

B

MM1S 72 hour

C

OPM2 24 hour

D

OPM2 72 hour

E

MM1R 24 hour

F

MM1R 72 hour

MM1S bioluminescence
read at 24 (A) and 72 (B)
hours after various
doses of etomoxir were
added. MM1S cells
were seeded at a cell
density of 40,000
cells/well. OPM2
bioluminescence read
at 24 (C) and 72 (D)
hours after various
doses of etomoxir were
added. MM1R
bioluminescence read
at 24 (E) and 72 (F)
hours after various
doses of etomoxir were
added.
*, p< 0.05;
****, p< 0.0001

1. We have seen a decrease in cell viability in our in vitro models with the MM1S, MM1R, and OPM2
multiple myeloma cell lines when treated with etomoxir only.
2. Our preliminary data showing that etomoxir decreased cell viability, suggests that multiple myeloma
may utilize fatty acid metabolism as a source of energy.
3. Combination treatments of etomoxir with other anti-myeloma drugs, such as bortezomib and
dexamethasone showed a significant decrease in cell viability when compared to the control in MM1S
and MM1R cell lines.
4. While we are seeing a trend in a reduction of cell viability with the use of etomoxir in all cell lines, more
research is required to confirm this data and refute any claims of off target effects.

FUTURE DIRECTIONS
1. Isolate mitochondria to run a SeaHorse assay to determine the dose of etomoxir that results in off
target effects on the electron transport chain.
2. Determine the exact doses of etomoxir in combination with bortezomib and dexamethasone that are
most effective in multiple myeloma cell lines.
3. Seed myeloma cells in direct, or indirect, co-culture with bone marrow adipocytes to investigate
whether etomoxir has a greater negative effect on cell viability in a high lipid environment.
4. Create a CPT1 knockdown model using lipofectamine and siRNA to see the effect of complete inhibition
of fatty acid oxidation without the risk of off-target effects.
5. Treat multiple myeloma cells with a combination of etomoxir and orlistat (fatty acid synthesis inhibitor)
to try to reduce cell viability and to determine the role of lipids in myeloma cells.
6. Create a drug combination therapy including etomoxir, orlistat, and anti-myeloma drugs.

REFERENCES
1. Kyle, R. A., & Rajkumar, S. V. (2008). Multiple myeloma. Blood, 111(6), 2962–2972.

2. Fazeli, P. K. et al. (2013). Marrow Fat and Bone—New Perspectives. J. Clin. Endocrinol. Metab. 98, 935–945.
3. Gatza, M. L., Silva, G. O., Parker, J. S., Fan, C., & Perou, C. M. (2014). An integrated genomics approach identifies drivers of
proliferation in luminal-subtype human breast cancer. Nature Genetics, 46(10), 1051-1059. DOI: 10.1038/ng.3073
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Loss of miR-199b promotes expansion of myeloid-committed
progenitors differentiated from bone marrow and spleen HSCs
Aidan McGrory1, Aldona Karaczyn1, Edward Jachimowicz1, Pradeep Sathyanarayana1
for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine

Abstract

Results

Methods
WT

miR-199b KO
Bone marrow (BM) and
spleen harvest

WT

KO
BM harvest

1º plating

CFU
Counting
GM 3534

2º plating

3º plating

GEMM 3434
CFU
Counting

BM cell
transplantation
to irradiated WT
mice

Blood sample at
4 and 8, 12
weeks

CFU
Counting

Figure 1. Experimental design for in vitro colonyforming unit (CFU) assays. Bone marrow and spleens
were harvested from N=3 wild type (WT) and miR-199b
KO mice. Cells were plated in MethoCult GM 3534 media
for myeloid progenitor differentiation or MethoCult GEMM
3434 medium that promotes multi-lineage differentiation.
Cells were kept at 37ºC with 5% CO2 and replated at 12
day intervals. Manual counting of cells was done after
imaging on STEMvision scanner.

Figure 2. Experimental design for in vivo BMT
transplantation study. Bone marrow from N=3 WT and
KO mice carrying a CD45.2 marker was harvested and
transplanted to irradiated WT mice carrying a CD45.1
marker. At 4, 8 and 12 weeks, blood samples were
taken from both mice for flow cytometry to determine
donor percentage of mature myeloid and lymphoid cells
in peripheral blood.
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Figure 3. miR-199b KO HSPCs from bone marrow (BM) have
decreased colony forming abilities on GM medium at first plating.
A) Representative images of colony forming assays for HSPCs
differentiating into myeloid lineages (CFU-GM) performed in BM cells
from WT and miR-199b KO mice (n=3) for 2.0 x 103 lineageneg c-kitpos
cells. B) Representative images of colony forming assays of miR-199b
null HSPCs on CFU-GEMM, directing cells to multilineage differentiation
(CFU-GEMM). Assays were performed in BM cells from WT and miR199b KO mice (n=3) for 2.0 x 103 lineageneg c-kitpos cells. C) Total CFUGM and CFU-GEMM for BM cells in WT and miR-199b KO mice.
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Figure 7. miR-199b KO HSCs have a greater ability to repopulate myeloid cells in the
irradiated host mice than WT HSCs. Donor chimerism (%) was measured at 4, 8 and 12 weeks
post-transplantation of BM from WT and miR-199b KO mice into sublethally irradiated host mice.
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Figure 4. miR-199b deletion decreases colony forming abilities of splenic HSPCs at first
plating. A) Representative images of colony forming assays for splenic HSPCs on GM
differentiation medium (CFU-GM) performed in WT and miR-199b KO mice (n=3) for 2.5 and 5.0 x
105 cells. B) Representative images of colony forming assays for granulocyte, monocyte, erythroid,
myeloid and megakaryocytes differentiation medium (CFU-GEMM) performed in spleen cells from
WT and miR-199b KO mice (n=3) for 2.5 and 5.0 x 105 cells. C) Total CFU-GM and CFU-GEMM for
spleen cells in WT and miR-199b KO mice.
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Figure 6. miR-199b KO mice show increased splenic myeloid progenitor proliferation as
compared to WT mice. A) Representative images of serial colony-replating assays of secondary
plating for myeloid progenitors (CFU-GM) performed in spleen cells from WT and miR-199b KO mice
(n=3) for 2.0 x 104 cells. B) Representative images of serial colony-replating assays of second
plating for granulocyte, erythroid, myeloid and megakaryocytes progenitors (CFU-GEMM) performed
in first plated spleen cells from WT and miR-199b knockout mice (n=3) for 2.0 x 104 cells. C)
Subsequent CFU replating assays for myeloid progenitors in CFU-GM media for 2.0 x 104 cells. D)
Subsequent CFU replating assays for multi-lineage progenitors in CFU-GEMM media for 2.0 x 104
cells.
***

5.0x105
cells

C

GEMM
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Donor chimerism
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Results: We found that miR-199b deletion decreases HSCs clonogenic potential, but
favors GM myeloid differentiation and propagation of myeloid-committed progenitors. CFU-GM
and CFU-GEMM were decreased in the splenic HSPCs from miR-199b KO mice as compared to
WT counterparts. These results showed that splenic hematopoiesis is altered in miR-199b KO
mice. CFU-GM assays revealed a similar behavior of miR-199b-null HSPC from both the bone
marrow and spleen niches; indicating that extracellular factors did not play a significant role in
such differences. Our transplantation study showed that miR-199b KO HSCs have a greater
ability to repopulate myeloid and lymphoid cells than WT HSCs.
Further exploration into the effect of miR-199b in HSC self-renewal and progenitor differentiation
will help us to understand the functional role of miR-199b in early hematopoiesis.

WT

Colony number per
5.0x105 total spleen
cells

Experimental Approach:
In vitro; In this study, we used a colony-forming unit (CFU) assay as validated in vitro that can
detect an increase or decrease in the frequency of hematopoietic stem and progenitor cells
(HSPCs) proliferation and/or changes in differentiation potential in response to stimulatory agents,
such as GM and GEMM. Therefore, CFU on GM and GEMM media was assessed to determine
proliferation abilities of HSPC from miR-199b KO bone marrow and spleen after primary,
secondary, and tertiary plating as compared to WT.
In vivo; A bone marrow transplantation study was utilized to assess the ability of miR-199b KO
HSC cells to repopulate blood cells in healthy host mice exposed to sublethal irradiation.

B

KO

Colony number of bone
marrow cells on GEMM semisolid medium

Aim: HSC behavior is regulated by its microenvironment, thus the goal of this study was to
assess whether the response of HSPCs lacking miR-199b to GM and GEMM depends on the
tissue microenvironment in which hematopoiesis occurs.

Results
GEMM

2.0x103 ckit+ cells

Colony number per
2.5x105 total spleen
cells

Hypothesis: Loss of miR-199b affects proliferation of HSCs and myeloid progenitors, and favors
myeloid differentiation.

WT

Colony number of bone
marrow cells on GM semisolid medium

Rationale: We and others have reported a significant down-regulation of microRNA 199b (miR199b) in bone marrow from AML patients. Recently, mRNA expression analyses revealed that
miR-199b is markedly enriched in hematopoietic stem cells (HSC) compartment, suggesting that
miR-199b may regulate HSCs function. Our flow cytometry analyses of bone marrow cells
showed elevated frequencies of primitive HSCs and myeloid progenitors in mice harboring
genetic deletion of miR-199b.

A

GM

Colony number of spleen
cells on GM semi-solid
medium

Background: Perturbed hematopoietic stem cell (HSC) homeostasis can cause blood cancers
including acute myeloid leukemia (AML). To avoid this, HSC proliferation, survival and
differentiation must be properly balanced. There is emerging evidence that microRNAs (miRNAs)
might be well suited to regulate these decisions. Indeed, reports suggests that dysregulation of
microRNA expression in HSCs can lead to AML development.

Colony number of spleen
cells on GEMM semi-solid
medium

1Center

***

Figure 5. miR-199b KO mice show increased proliferation of myeloid-committed progenitors.
A) Representative images of serial colony-replating assays at secondary and tertiary plating for
myeloid-committed cells (CFU-GM) derived from WT and miR-199b KO progeny cells at first plating.
Assays were performed for 2.0 x 104 cells from the first plating. B) Representative images of serial
colony-replating assays at secondary and tertiary plating for granulocyte, erythroid, myeloid and
megakaryocytes progenitors (CFU-GEMM) derived from WT and miR-199b KO mice (n=3) at first
plating. Assays were performed for 2.0 x 104 cells. C) Subsequent CFU plating assays for myeloid
progenitors in CFU-GM media for 1.0 x 104 and 2.0 x 104 cells. D) Subsequent CFU plating assays
for multilineage progenitors in CFU-GEMM media for 2.0 x 104 cells.

In conclusion, our results indicate that attenuation of miR-199b activity
promotes myeloid progenitor proliferation. We found that miR-199b deletion
favors myeloid lineage commitment and expansion of myeloid progenitors
when HSPCs were isolated either from BM or spleen, suggesting that these
HSPCs features result from intrinsic changes rather then niche alterations.
Reduced colony forming abilities of splenic HSPC in miR-199b KO mice
suggest regulatory effects of miR-199b on splenic hematopoiesis. Future
studies will be focused to understand the mechanism of miR-199b regulation
of myeloid progenitor lineage commitment.
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Modeling Clear Cell Renal Cell Carcinoma: Characterization of the Tumor
Extracellular Matrix
Anna Deck, Kyle Bond, Peter Brooks, Leif Oxburgh
Maine Medical Center Research Institute

B Tp18-S1081
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Figure 2.
A

Epitope
XL313

Figure 2: A) PCA analysis of tumor and normal mass spectrometry data after mass spectrometry acquisition. Noted distinct clustering of
tumor and normal cells. B) Differences in core ECM proteins between tumor and normal generated based on p-values <=0.05 from
SWATH analysis. Overlapping collagen proteins were identified based on peak abundance analysis of the non-significant pool.

Adapted with permission from Dr. Brooks

• Cell isolation and characterization plan:

• Mass spectrometry: Tumor and normal tissues depleted of cells run through data
independent acquisition LCMS mass spectrometry to characterize proteins of the ECM,
and analyzed via SWATH.
• Differential adhesion: 786-Os were seeded onto collagen IV and denatured collagen IV.
Optical density was used to measure mean cell adhesion and western blots of
downstream collagen signaling molecules were run. 786-O conditioned media was
collected and analyzed via western blot for secretion of collagen epitopes.
• Immunohistochemistry: Paraffin embedded sections were stained with anti-XL313 and
Collagen I, III, and IV cocktail following previously developed ECM staining procedure.
H&E and Trichrome staining performed by MMCRI Histology Core.

C
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40x

Conclusions

Cell Surface Receptors
avb3

Methods

B

Figure 4: A) H&E sections of ccRCC, 20x. B) Trichrome staining, 20x. C) Immunofluorescence of paraffin sections for XL313 collagen
epitope, 20x. Insert, 40x. Images were taken of matching regions for each tumor, scale bars 200 µm and 50 µm in 40x.

C-ter.

Amino Acid Sequence
RGDKGE

Tp18-S114

B

Collagen types-I, II, III
N-Ter

Tp18-S109

Tp18-S108

Trichrome

Figure 1: A) Summary of specific ccRCC patient diagnostics regarding used for current study. B) Validation staining of ccRCC cell isolation.
After culture for three passages, cells were collected using cytospin and stained for ccRCC markers(CK18 and Vimentin) and fibroblast markers
(Vimentin and PDGFRβ) and costained with DAPI.

Hidden epitopes in collagen of extracellular matrix

Mechanical damage or proteasemediated exposure of cryptic
epitopes

A

H&E

A Tumor

Figure 4.

Collagen XL313 DAPI

Introduction
• Developing a ccRCC model requires isolation of ccRCC cells; cells were isolated from
tumors, grown in culture, and depleted of fibroblasts.
• Three possibilities exist regarding how ECM changes,; new ECM deposited by tumors, ECM
is degraded, or ECM is remodeled and exists in an alternate form. We used mass
spectrometry and immunohistochemistry to explore these options.
• 786-Os, a ccRCC cell line, were grown on normal and denatured collagen IV to study which
environment is more favorable for cancer growth. Secretion of collagen was also studied.
• Remodeling of ECM by damage or proteases can release previously hidden collagen epitopes
that affect angiogenesis. In this study we targeted XL313, a collagen epitope linked to
increased angiogenesis and inflammation in other cancer types and shown to be secreted by
macrophages1.
Representation of distinct cryptic regulatory
Effects of remodeling on cryptic epitopes
elements identified in the ECM protein collagen

Results

Results
Figure 1.

CK18 PDGFRβ Vimentin DAPI

Abstract
Renal cell carcinoma (RCC) is the most common kidney cancer, affecting nearly 64,000
new patients every year2,3. Clear cell renal cell carcinoma (ccRCC) is the most common form of
RCC, yet few treatment options exist for patients with this disease2. Due to tumor heterogeneity
and patient differences, developing personalized treatments is a high priority for treating afflicted
patients. A major challenge in developing patient specific models is the complexity of the tumor
microenvironment (TME). One important component of the TME is the extracellular matrix
(ECM), which has not been well characterized in ccRCC. Here we sought to understand the
composition and structure of ECM in individual patients. Tumor and matching normal ECM
and cells were isolated from patient biopsies and characterized through LCMS mass
spectrometry and immunofluorescence. Independent data acquisition and analysis using SWATH
identified drastic changes in collagen content between tumor and normal cells. It was further
determined that a denatured collagen environment increased cell adhesion and Akt signaling
using an in vitro cell adhesion assay with the 786-O ccRCC cell line. XL313, a truncated
RGDKGE collagen epitope, was shown to be secreted by 786-O cells. Immunohistochemical
staining of patient tumors showed aberrant expression of XL313 throughout specific ccRCC
tumors. These findings suggest that we have designed a cell isolation method that is viable to be
used to create a ccRCC model to study cancer-ECM interactions. Additionally, the findings show
a potential role of denatured collagen in ccRCC growth.

Figure 3.
A

B

• Method used to isolate cells from ccRCC tumors efficiently purifies cancer cells based on
marker analysis. These cells would be appropriate for downstream disease modeling
studies.
• Drastic changes in ECM composition and structure exists between normal and tumor
ccRCC tissue. The relative abundance of collagens varies significantly between the two
groups.
• 786-Os preferentially adhere to denatured collagen IV, which leads to increased
downstream α5 integrin signaling.
• Secretion of denatured collagen XL313 by 786-Os suggests a novel role of XL313 in
ECM remodeling in ccRCC.
• XL313 collagen epitopes are highly expressed in tumors Tp18-S108 and Tp18-S109, but
not in Tp18-S114, indicating both intratumor and patient heterogeneity.
Future Directions
• Differential adhesion onto denatured collagen repeated with isolated primary ccRCC cells.
• Confirm that XL313 is secreted by primary ccRCC cells, as well as other ccRCC cell lines.
• Staining for αv alongside other TME component cells should be performed to validate
ability for cells to interact with XL313 epitope.
• Treatment of cell lines with anti-XL313 and measuring effect using a collagen invasion
assay.
• Xenograft 786-O cells into immune compromised mice and treatment with XL313
antibody to understand the role of XL313 on tumor growth in vivo
Acknowledgements

C
XL313

Figure 3: A) 786-O cells were seeded on natural and denatured collagen IV. Cell adhesion was measured using optical density. B) Western
Blot of downstream signaling molecules involved in αV integrin signaling pathway following seeding onto natural or denatured collagen
IV. C) Western blot of 786-O conditioned media 786-Os after 72 and 48 hours identified XL313 (~15kb). Raw, a macrophage cell line,
was used as an XL313 positive control.
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Incidence and Characteristics of Opioid-Related Cardiac Arrests at Maine Medical Center

Bailey West1,2, Teresa May3, John Dziodzio3, Tyler Nussinow1, Barbara McCrum3, Christine Lord3, Ashley Eldridge3, Deanna Williams1, Lee Lucas4, Philip Stone3, Richard R. Riker3, David B. Seder3
1Maine Medical Center Research Institute, Scarborough, ME, 2Honors College, The University of Maine, Orono, ME,
3Department of Critical Care Services, Maine Medical Center, Portland, ME, 4Center for Outcomes Research, Portland, ME

Abstract

Results

Results
Table 3. Outcomes of non-ORCA and ORCA patients.

• The opioid epidemic is a growing public-health concern, particularly in Maine [1], and misuse of opioids can lead to
cardiopulmonary arrest [2]. In this study, we evaluated the incidence of opioid-related cardiac arrest (ORCA) admitted to Maine
Medical Center (MMC) during 5 years between January 2013 and December 2017, and the differences in baseline characteristics,
hospital course, and outcomes between ORCA and non-opioid-related cardiac arrest (non-ORCA) patients.

Outcome
Non-ORCA (n = 466)
ORCA (n = 51)
P value
Hospital LOS (median [IQR])
6 (3, 12)
8 (4, 13)
0.048
ICU LOS (median [IQR])
4 (3, 7)
6 (4, 10)
0.0068
Condition at hospital discharge
Dead
251 (56%)
28 (55%)
0.155
GCS<8/noninteractive
5 (1%)
2 (4%)
0.7
Disorientated
16 (4%)
2 (4%)
0.7
Oriented
174 (39%)
18 (35%)
0.6
Agitated
2 (0.4%)
1 (2%)
0.28
Calm
39 (9%)
3 (6%)
1 (NS)
Nonambulatory
21 (5%)
2 (4%)
0.4
Ambulatory
148 (33%)
14 (27%)
0.9
CPC at hospital discharge
1
46 (10%)
3 (6%)
0.5
2
94 (21%)
11 (22%)
1 (NS)
3
41 (9%)
5 (10%)
0.8
4
5 (1%)
2 (4%)
0.155
5
255 (57%)
30 (59%)
0.9
CPC = good
140 (32%)
14 (27%)
0.6
Discharge diposition
Home
93 (21%)
11 (22%)
0.9
Inpatient rehabilitation
66 (15%)
7 (14%)
1 (NS)
Inpatient ventilator unit
2 (0.4%)
0
1 (NS)
Skilled nursing
20 (4%)
2 (4%)
1 (NS)
Hospice
2 (0.4%)
0
1 (NS)
Died after withdrawal of life support
220 (49%)
25 (49%)
1 (NS)
Died despite full support
30 (7%)
5 (10%)
0.39
Life support withdrawn
229 (53%)
26 (55%)
0.9
If yes, cause of WLST
Severe brain injury
169 (57%)
26 (81%)
0.0075
Patient intent not to be treated aggressively
69 (23%)
3 (9%)
0.11
Multi-organ failure
44 (15%)
19 (37%)
0.000542
Pre-existing advance directives
13 (4%)
1 (3%)
1
Unstable circulation
41 (14%)
19 (37%)
0.000169
Medical co-morbidity
39 (13%)
1 (3%)
0.15
If yes, day of WLST
Within 48 hours from admission
87 (20%)
5 (10%)
0.126
Day 3 - 4
60 (13%)
5 (10%)
0.66
Day 5 - 6
32 (7%)
3 (6%)
1 (NS)
After day 6
51 (11%)
14 (27%)
0.0034
Unless otherwise reported, data are presented as number and percentage.
Abbreviations: LOS - length of stay; ICU - intensive care unit; GCS - Glasgow Coma Scale; CPC - Cerebral Performance Category;
WLST - withdrawal of life support

• A retrospective review was performed on medical records of MMC cardiac arrest patients and in prospectively collected registry
data. An arrest was classified as an ORCA if it had no alternative explanation and met at least one of the following criteria: 1) EMS
suspected the arrest was opioid-related, 2) the physician team suspected the arrest was opioid-related, or 3) an opioid-positive
toxicology screen [3]. Statistical methods used include the Wilcoxon rank-sum test and Fisher’s exact test. A P-value less than or
equal to 0.05 was considered significant.
• Of 497 patients 51 (10.3%) had ORCA. ORCAs at MMC had increased from 15 in 2013-14 to 26 in 2016-17, a 73% increase.
ORCA patients were significantly younger and healthier than other cardiac arrest patients but were more likely to have withdrawal
of life support due to severe brain injury. There was no significant difference in functional outcome and in-hospital mortality.
• Admissions to MMC for opioid-related cardiac arrest rose dramatically over 5 years. The demographics and clinical characteristics
of opioid-related cardiac arrest differ from other forms of cardiac arrest, while outcomes were similar. More research into the
pathophysiology of ORCA is needed to better treat this population.

Introduction

Table 1. Demographics and clinical features of nonORCA and ORCA patients.

Opioid-related cardiac arrest (ORCA)
Non-ORCA

?

ORCA

?

?

Demographics
Age (years) [mean±SD]
Female
Pre-arrest diseases
Previously healthy
Arrhythmia
Heart failure
Myocardial infarction
CCI [median (IQR)]
Comorbid conditions
CPC 1 prior to arrest
Clinical features
Out-of-hospital arrest
Witnessed
Initial rhythm VT/VF
Bystander CPR
Poor GCS motor subscore
Total ischemic time (min)
[median (IQR)]
No-flow interval (min)
[median (IQR)]

Figure 1. Venn diagram representing the unknown
similarities and differences between ORCAs and nonORCAs.

Methods
•

EMS suspects ORCA?
Yes
No

Physician team suspects
ORCA?

•
•

Yes
Alternative
explanation?
Yes

non-ORCA using a system based on the

outcomes data collected from the
(INTCAR).

No

Alternative
explanation?
Yes

Demographic, hospital course, and
International Cardiac Arrest Registry

Yes

No

Non-ORCA

Each arrest was classified as ORCA or
criteria described in [3].

No

Opiate-positive toxicology
screen at admission?

performed for patients admitted to MMC

Non-ORCA (n =
446)
59.4 ± 15.8
142 (32%)

ORCA (n =
51)
40.7 ± 14.5
14 (27%)

P value
<0.0001
0.6

55 (12%)
84 (19%)
77 (17%)
60 (13%)
3 (1, 5)
2 (1, 3)
397 (90%)

13 (25%)
2 (4%)
2 (4%)
3 (6%)
0 (0, 1)
0 (0,1)
49 (98%)

0.016
0.005
0.014
0.18
<0.0001
<0.0001
0.07

327 (74%)
346 (79%)

47 (94%)
27 (55%)

0.0008
0.0006

220 (52%)

7 (15%)

<0.0001
0.26
0.6

81 (29%)
313 (73%)

8 (20%)
37 (77%)

17 (10.3, 27)

16 (10, 25)

0.9

4 (1, 7)

5 (1.5, 8.5)

0.16

285 (64%)

30 (59%)

0.5

Figure 6. Comparison of pre-arrest health between nonORCA and ORCA patients.

Conclusions

Unless otherwise reported, data are presented as number and
percentage.
Abbreviations: CCI - Charlson Comorbidity Index; CPC - Cerebral
Performance Category; VT/VF - ventricular tachycardia/ventricular
fibrillation; CPR - cardiopulmonary resuscitation; GCS - Glasgow Coma
Scale

Non-ORCA

July 2018.
No

Yes

Shock on admission

A retrospective chart review was
for cardiac arrest from January 2013 to

Alternative
explanation?

Figure 5. Rate of ORCA and non-ORCA between January 2013 and
July 2018.

Figure 4. Incidence of ORCA at MMC 2013-2017.

•

These characteristics were compared

•

Statistical analyses used include Fisher’s

between ORCA and non-ORCA patients.
exact test and the Wilcoxon signed-rank
test.

•

No

A P value less than or equal to 0.05 was
considered significant.

ORCA

Figure 2. Method for classifying cardiac arrests as ORCA or non-ORCA.
An arrest was considered ORCA if it met at least one of the following criteria
with no alternative explanation: 1) EMS suspects ORCA, 2) Physician team
suspects ORCA, 3) Opiate-positive toxicology screen. Based on reference 3.

Figure 3. The International Cardiac
Arrest Registry (INTCAR).

Hypotheses
•

The rate of ORCAs increased at MMC and statewide from 2013 to 2018

•

ORCA patients demographics and clinical features differ from other cardiac arrests

•

ORCA patients have worse functional outcomes than non-ORCA cardiac arrest patients

•

The pathophysiology of ORCA differs from other cardiac arrest populations

Published by MaineHealth Knowledge Connection, 2019

ORCA

Older

More
comorbidities

Table 2. Hospital course for non-ORCA and ORCA
patients.

Non-ORCA (n =
Treatments/Tests
466)
ORCA (n = 51) P value
TTM administered
440 (99%)
50 (98%)
0.42
Target temperature (◦C)
33
63 (14%)
4 (8%)
0.28
34
4 (1%)
0
1 (NS)
35
29 (7%)
1 (2%)
0.35
36
24 (5%)
2 (4%)
1 (NS)
Coronary angiography
161 (37%)
5 (10%)
9.99E-05
PCI
74 (17%)
2 (4%)
0.013
Vasopressors / inotropes
used during ICU stay
409 (93%)
44 (88%)
0.155
Mechanical circulatory
support
424 (97%)
48 (94%)
0.2
Echo (within 12 h ROSC)
Normal >50%
104 (23%)
10 (20%)
0.6
Moderately impaired 3049%
90 (20%)
2 (4%)
0.0022
Severely impaired <30%
83 (19%)
5 (10%)
0.173
Echo not done
162 (36%)
33 (65%) 0.000124
MRI
21 (42%)
93 (21%)
0.0022
If MRI, when (days postROSC) [median (IQR)]
4 (3, 5)
4 (3, 5)
0.9
Complications
Pneumonia
153 (34%)
26 (51%)
0.021
Seizures - clinical
None
362 (82%)
33 (66%)
0.0134
Yes partial
11 (2%)
1 (2%)
1
Yes generalized
50 (11%)
13 (26%)
0.0065
Yes subtle / non
convulsive
5 (1%)
3 (6%)
0.038
Yes before temerature
management
19 (4%)
4 (8%)
0.28
Yes during temperature
management
40 (9%)
9 (18%)
0.075
Yes after temperature
management
10 (2%)
4 (8%)
0.044
Myoclonus
248 (56%)
22 (44%)
0.13
Data are presented as number and percentage.
Abbreviations: TTM - targeted temperature management; PCI percutaneous coronary intervention; ICU - intensive care unit; ROSC return of spontaneous circulation; MRI - magnetic resonance imaging

VT/VF more likely
Severe brain
injury less likely
Figure 7. Additional interventions for non-ORCA and ORCA
patients.

Younger
Ischemic
time
GCS motor
score

Overall
Additional cardiac outcome
interventions more
likely

Fewer
comorbidities

VT/VF less likely
Severe brain
injury more
likely
Additional cardiac
interventions less
likely

Figure 10. Venn diagram representing the similarities and
differences between ORCA and non-ORCA patients.

•

The incidence of ORCAs at MMC has increased by

•

ORCA patients were younger with fewer comorbid

•
•

ORCA patients were less likely to have VT/VF.

•

ORCA patients were less likely to undergo

•

There was no difference in ischemic time or

73% from 2013 to 2017.
conditions.
ORCA patients were likely to have more severe
brain injuries.
additional cardiac interventions.
Glasgow Coma Scale motor subscore on
presentation.

•

There was no difference in the rate of in-hospital
mortality and good functional outcome between
ORCA and non-ORCA patients.

Figure 8. Hospital and ICU LOS for non-ORCA and ORCA
patients.

Next Steps
•
•

1.
2.
3.

Figure 9. Condition at hospital discharge for non-ORCA and
ORCA patients.

Compare patterns of brain injury by serology and MRI between ORCA and non-ORCA patients
Characterize ORCAs geographically throughout Maine
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Spry1 deficiency in mice shows fat depot specific alterations in adipose tissue
responses to a high-fat Western Diet
Bridget Mellon1, Shivangi Pande2, 3,Xuehui Yang3 and Robert Friesel2,3
1 Biology Department, Gordon College, 255 Grapevine Rd. Wenham, MA 01984
2 Graduate School of Biomedical Sciences and Engineering, University of Maine
3 Maine Medical Center Research Institute, 81 Research Dr, Scarborough, ME 04074

ABSTRACT

The aim of this project was to investigate the effects of Spry1 deficiency on
adipose tissue responses to a Western Diet. Spry1 is highly expressed in the
adipocytes and adipocyte progenitors. We looked for a specific “coronal
structures” around adipocytes that are indicators of fibrosis. We
observed decreased coronal structures in the epididymal adipose tissue of Spry1
-/- mice fed a WD compared to Spry1+/+ mice. Our results also demonstrated that
Spry1 -/- mice have a higher incidence of KLF4 and F4/80 positive cell staining
compared with Spry1+/+ mice, indicating that the difference in fibrosis may be
due to differential expression of the above markers. Thus, loss of Spry1 may be
protective against Western Diet induced adipose tissue dysfunction.

RESULTS

CONCLUSIONS

Figure 1: X-gal staining of Spry1-/- mice showing expression of Spry1 in the adipocyte cells
in eWAT and iWAT tissue.

Figure 2: H&E staining of eWAT showing less “crown-like” structures surrounding
adipocytes of Spry1 -/- mice compared to Spry1+/+ mice.

•

We observed decreased crown-like structures in the adipose tissue of
Spry1-/- mice fed a WD when compared to Spry1+/+ mice. This suggests
that Spry1 deficiency may alter the response of adipose tissue to
hypercholesterolemia and this response leads to a less fibrotic
appearance.

•

There appeared to be an increase (in both intensity and quantity) of F4/80
and KLF4 positive cells in the adipose tissue of Spry1-/- mice compared
to Spry1+/+. This suggests an increase in macrophage infiltration of
Spry1-/- adipose tissue.

•

Fibrosis is usually a result of macrophage accumulation (in this case,
hypercholesterolemia- induced) and/or aging, and based upon our
observed increase in F4/80 immunostaining we expected fibrosis to be
higher in Spry1 -/- mice fed a WD. The unexpected presence of less
fibrotic adipose tissue in the Spry1-/- mice (especially eWAT) suggests
Spry1 deficiency disrupts the development of fibrosis under
hypercholesterolemic conditions. Understanding the role of Spry1 in
adipose tissue responses to a WD requires further study and may
provide unique opportunities for the treatment obesity, diabetes and
cardiovascular disease.

•

It appears that Spry1 -/- mice, while they have increased atherosclerosis,
also have more normal (healthier) looking adipose tissue when fed a
Western Diet.

INTRODUCTION
Spry1 -/-

Spry1 +/+

Atherosclerosis, an inflammatory disease characterized by arterial wall thickening
and plaque accumulation, is a major cause of death worldwide.
It presents itself as an inflammatory
response, initiated by activation of the
endothelial layer surrounding the vessel
lumen. This activation then induces a
phenotypic transition of the smooth muscle
cells, from a dormant, contractile state, to a
proliferative and migratory, synthetic state.

Figure 3 : Expression of KLF4 in eWAT and iWAT of HFD fed Spry1 -/- and Spry1+/+
mice

x200
Spry1 +/+

Our lab has established that Spry1, a
regulator of receptor tyrosine kinase (RTK)
signaling, plays a critical role in the
maintenance of the contractile VSMC
phenotype by inhibiting their migration. Spry1
is highly expressed in both the fibroblasts
and smooth muscle cells in the vasculature of
the heart, as well as in the adipocyte cells.

Spry1 -/-

x200

References
x200

x200
Spry1 -/-

Spry1 +/+
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Complex Regulation and Function of the Inflammatory Smooth Muscle
Cell Phenotype in Atherosclerosis. Journal of Vascular Research, 47(2),
168-180. doi:10.1159/000250095

MATERIALS and METHODS
Figure 4: Expression of F480 in eWAT and iWAT for HFD fed
Spry1 -/- and Spry1+/+ mice

Spry1 -/-

Spry1 +/+

• Mice were fed a 45% fat-kcal atherogenic diet.
• AAV-PCSK9-D377Y was injected into the mice
in order to reduce LDL-receptor expression in
the liver, inhibiting cholesterol absorption from
the blood and creating a hypercholesterolemic
state.

x200

x200
Spry1 -/-

Spry1 +/+

• Analysis of adipose tissue included
immunohistochemistry with F4/80 and KLF4
antibodies, which are markers of macrophages
and stem cells respectively.

HFD feeding
for 12 weeks

Yang, X., Gong, Y., He, Q., et al., (2017). Loss of Spry1 attenuates vascular
smooth muscle proliferation by impairing mitogen-mediated changes in
cell cycle regulatory circuits. Journal of Cellular Biochemistry, 119(4),
3267-3279. doi:10.1002/jcb.26486
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Crafting a resource guide for curriculum building in EM POCUS Continuing Medical Education
Campbell Belisle Haley, Tufts University School of Medicine Maine Track Program

Abstract + Background
Ultrasonography (ultrasound) is a technology that uses high frequency sound waves to
generate moving images of tissue. Point of care ultrasound (POCUS) is ultrasound brought to
the patient and performed in real time. POCUS began in the 1990s as a tool used to improve
diagnosis, procedures, and screening in multiple specialties. POCUS has become particularly
important in emergency departments. This project explored the scope of POCUS training in
emergency medicine (EM), compared ways that competency in POCUS is assessed, and used
literature review to create an compilation of resources that aims to improve competencybased POCUS education of Maine EM physicians.

Scan for early intrauterine pregnancy

Abdominal
Aorta Lumen

Components of a high-quality CME Curriculum

Determine “core” ED
applications of POCUS
Create a way to assess
needs of physician
population

2. Integrated feedback
mechanisms:
How will you determine what they
learned?

Review assessment tools
available + their validity

3. Detailed instructional methods:
How will you teach them this material?

Evaluation of abdominal aorta

Liver

Sample SDOT Checklist for Ultrasound Competency Assessment
Tolsgaard et al, PLoS One, 2013

Right Kidney
FAST Exam, RUQ Scan
All scan images from: https://www.acep.org/sonoguide/

Emergent Cardiac Imaging: Parasternal
Long Axis View

•
•
•

Manual search and MEDLINE search for ultrasound
training recommendations
MEDLINE search for previous ultrasound assessment
tools
Consultation with author of previous needs
assessment tool to adapt for Maine

Patientcentered
needs

Providercentered
needs

Resource Guide for CME in POCUS:

 Summary of expert guidelines for core applications
and establishment of 3 tiers according to consensus
opinion
 Needs assessment tool to determine training goals
 Compilation of previous assessment tools for each
Tier 1 ultrasound application

Existing
clinical
resources

Political,
administrative
considerations

Existing
physical
resources

Conclusions
1)

Needs
assessment

Adapted from Henwood et al, Annals of Emergency Medicine, 2014

Published by MaineHealth Knowledge Connection, 2019

IJV Scan for Central Line Procedural
Guidance

2 surveys and one structured interview were developed to assess
the ultrasound training needs of Maine emergency physicians.

“Writing a Curriculum”, University at Buffalo Office of Continuing Medical Education, http://medicine.buffalo.edu/cme/planning_cme/writing_a_curriculum.html

Methods

literature review, 8 had evidence of validation studies

3 Tiers of Core POCUS Applications were developed according to
consensus expert opinion

Objectives
1. Review guidelines from experts and professional
organizations to determine core applications of EM POCUS
2. Identify pre-existing ultrasound assessment tools and review
associated validity evidence
3. Develop a needs-assessment survey to determine the current
use and training needs of ultrasound in Maine emergency
departments

1. Clear educational objectives:
What will your participants
learn?

26 published assessment tools were identified through

Results

2)
Geographic
issues

3)

Objectives for a CME curriculum should be based on a)
expert opinion of required applications for EM POCUS and
b) assessment of training needs for a physician population
Many tools exist to assess skills in emergency POCUS, but
few have been tested for validity
OSCE/SDOT checklists have the most validity evidence, but
this assessment method requires presence of US experts

Acknowledgments
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Simulation team for supporting me in this project, Dr. Christina Wilson and Dr. David McKenzie for their guidance on this project,
and the Maine Medical Center Research Institute summer program for facilitating this research experience. I would like to dedicate
this poster to Dr. Randy Darby, who inspired me to look deeper into how we measure quality and competency in medical
education.
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Time Course of Cognitive Change after Severe Hypoglycemia
Charlotte	
  Benoit1,	
  Lori	
  Brodsky2,	
  MN,	
  FNP,	
  Irwin	
  Brodsky2,	
  MD,	
  MPH

1Maine	
  Medical	
  Center	
  Research	
  Institute,	
  2Maine	
  Medical	
  Partners	
  Endocrinology	
  and	
  Diabetes	
  Center

Abstract
Hypoglycemia,	
  or	
  episodes	
  of	
  low	
  blood	
  sugar,	
  is	
  
particularly	
  prevalent	
  in	
  people	
  with	
  type	
  1	
  diabetes.	
  This	
  is	
  
because	
  taking	
  too	
  much	
  exogenous	
  insulin	
  can	
  lead	
  to	
  
extremely	
  low	
  blood	
  sugar	
  levels.	
  This	
  study	
  focuses	
  on	
  the	
  
cognitive	
  effects	
  of	
  severe	
  hypoglycemia,	
  which	
  requires	
  the	
  
aid	
  of	
  another	
  person,	
  and	
  particularly	
  Grade	
  4HG,	
  defined	
  
as	
  episodes	
  of	
  low	
  blood	
  sugar	
  that	
  result	
  in	
  seizure	
  or	
  
unconsciousness.	
  It	
  is	
  well	
  known	
  that	
  during	
  and	
  
immediately	
  after	
  a	
  severe	
  hypoglycemic	
  episode,	
  brain	
  
functioning	
  is	
  slower	
  and	
  thinking	
  can	
  be	
  ‘foggy’.	
  This	
  study	
  
addresses	
  the	
  cognitive	
  effects	
  of	
  severe	
  hypoglycemia	
  in	
  
adolescents	
  with	
  type	
  1	
  diabetes	
  over	
  the	
  span	
  of	
  a	
  month,	
  
instead	
  of	
  just	
  in	
  the	
  immediate	
  aftermath	
  of	
  an	
  episode.	
  
Participants	
  ages	
  12-‐21	
  take	
  a	
  computerized	
  test	
  to	
  measure	
  
memory,	
  reaction	
  time,	
  and	
  visual	
  processing,	
  in	
  order	
  to	
  
assess	
  their	
  general	
  cognitive	
  functioning.	
  Data	
  from	
  a	
  pilot	
  
study	
  suggests	
  that	
  adolescents	
  who	
  experience	
  an	
  episode	
  
of	
  Grade	
  4HG	
  have	
  impaired	
  visual	
  and	
  verbal	
  memory	
  1-‐2	
  
weeks	
  later.	
  Data	
  also	
  suggests	
  that	
  visual	
  and	
  verbal	
  
memory	
  recover	
  by	
  one	
  month	
  after	
  the	
  episode.	
  Based	
  on	
  
these	
  preliminary	
  findings,	
  it	
  seems	
  that	
  certain	
  cognitive	
  
abilities	
  continue	
  to	
  be	
  impaired	
  even	
  after	
  hypoglycemic	
  
symptoms	
  are	
  no	
  longer	
  noticeable.	
  The	
  study	
  team	
  
continues	
  to	
  conduct	
  research	
  and	
  acquire	
  data	
  from	
  
adolescents	
  who	
  have	
  recently	
  experienced	
  severe	
  
hypoglycemia,	
  as	
  well	
  as	
  control	
  subjects.

Methods
The	
  study	
  team	
  is	
  testing	
  adolescents	
  ages	
  12-‐21	
  who	
  have	
  
recently	
  experienced	
  an	
  episode	
  of	
  Grade	
  4HG,	
  adolescents	
  
who	
  have	
  type	
  1	
  diabetes	
  but	
  have	
  not	
  recently	
  experienced	
  
severe	
  hypoglycemia,	
  as	
  well	
  as	
  adolescents	
  without	
  diabetes.	
  
Each	
  participants	
  takes	
  a	
  25	
  minute	
  computerized	
  test	
  originally	
  
meant	
  to	
  assess	
  concussions	
  called	
  the	
  ImPACT test.	
  The	
  testing	
  
is	
  conducted	
  four	
  times	
  over	
  the	
  course	
  of	
  a	
  month.

Hypothesis
The	
  study	
  team	
  hypothesized	
  that	
  adolescents	
  ages	
  12-‐
21	
  would	
  experience	
  a	
  temporary	
  impairment	
  in	
  their	
  
visual	
  and	
  verbal	
  memory	
  1-‐2	
  weeks	
  after	
  experiencing	
  
an	
  episode	
  of	
  Grade	
  4HG.

Figure	
  1.	
  Symptom	
  scores	
  of	
  
participants	
  who	
  had	
  experienced	
  an	
  
episode	
  of	
  Grade	
  4HG;	
  2013.	
  Used	
  with	
  
permission	
  from	
  Irwin	
  Brodsky,	
  MD.

Figure	
  3.	
  Verbal	
  memory	
  scores	
  of	
  
participants	
  who	
  had	
  experienced	
  an	
  
episode	
  of	
  Grade	
  4HG,	
  and	
  control	
  
subjects;	
  2013.	
  Used	
  with	
  permission	
  
from	
  Irwin	
  Brodsky,	
  MD.

Adapted	
  from	
  ImPACT Applications,	
  Inc.,	
  2018

Figure	
  2.	
  Scores	
  of	
  visual	
  motor	
  speed,	
  verbal	
  memory,	
  and	
  cognitive	
  efficiency	
  of	
  
participants	
  who	
  had	
  experienced	
  an	
  episode	
  of	
  Grade	
  4HG;	
  2013.	
  Used	
  with	
  permission	
  
from	
  Irwin	
  Brodsky,	
  MD.

Introduction

Summary & Conclusion
-‐ Visual	
  memory	
  is	
  impaired	
  in	
  adolescents	
  with	
  type	
  1	
  diabetes	
  1-‐
2	
  weeks	
  after	
  experiencing	
  an	
  episode	
  of	
  severe	
  hypoglycemia.	
  
Adapted	
  from	
  ImPACT Applications,	
  Inc.,	
  2018

-‐ Verbal	
  memory	
  is	
  impaired	
  in	
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  with	
  type	
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  after	
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  an	
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  of	
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-‐ The	
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  are	
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  and	
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  by	
  one	
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  after	
  an	
  episode	
  of	
  severe	
  
hypoglycemia.
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Needs Assessment and Quality Improvement of Pre-Transplant Patient Education
Elisabeth Lualdi, Dr. Paul Han, Jessica Begley, Dr. James Whiting
for the Maine Transplant Center

•

• Nationally, more than 115,000 patients are on
the waiting list for a life-saving kidney
transplant.
• At the Maine Transplant Center (MTC), 100
patients are on the waiting list, and about 50
transplants are performed in a given year.
• Patient Education at the MTC consists of a
single educational class before evaluation.
• Educational class creates scheduling demands
that delay evaluation & treatment.
• Many transplant candidates lack thorough
understanding of treatment options.
• Knowledge deficits impede appropriate care
following transplantation.

To improve the educational system for patients at
the Maine Transplant Center, aimed at facilitating
informed and shared decision making.
To conduct a needs assessment, based on literature
review and key informant interviews, guiding efforts
to redesign the educational intervention and identify
areas for improvement.

•

10 Weeks in a Nutshell

•
•
•
•

Patient Shadowing
Class Attendance
Literature Review
Patient Phone
Interviews: recent
class attendees

•
•
•
•

Staff Interviews
Presentation to
Transplant Team
Self-education on health
literacy
CDC scanning of
content delivered during
class (power point and
handouts)

Conceptual Models
2.
1.

A needs assessment was conducted to explore
ways to improve the educational system at MTC.
Findings from a literature review and key
informant interviews with MTC clinicians and
patients revealed many gaps in MTC patient
education.
Using the SDM and TTM models as conceptual
frameworks for redesigning the system, an
alternative educational pathway to treatment was
proposed.
The educational class has been reformatted into
an online, modular based program offered to
patients as an alternative. At the same time,
educational handouts are being refined to
enhance readability.

Results

Objectives + Methods

Introduction + Abstract

•
•

•
•
•
•
•

Patient Interviews
MTC Clinician Interviews
45% of patients responded
Patients should be given
• Only
correctly to a fundamental piece of
access to more resources for
information: that you have to take
information.
anti-rejection medications for the
Due to the volume of new
life of your transplant. More than
referrals, patients have to wait
50% of patients reported being
a significant amount of time
very unsatisfied with the progress
before they are booked for a
of their treatment.
class.
Patients are overwhelmed with • Only 33% had completed some
clearances (explained in the class)
information.
prior to Visit 1.
Patients have low health
literacy.
Literature Review
Using TTM, patients educated according to their specific readiness
stage are 2 times more likely to engage in a recommended health
behavior in the next 6 months than those with generalized
recommendations.6
Meta-analysis of 6 studies found that 40% of patients on dialysis
lack health literacy in their ability to take care of themselves and
change certain behaviors to support health.4
An online program (educating patients on sun protection after a
kidney transplant) had direct ties to Skelton’s Recommendations (see
Methods section). Patients with initial low health literacy made
significantly greater gains in knowledge than patients with adequate
health literacy after completing the program.5

Prototype: A 5 Part Online Power Point with Audio.
Alternative Pathway for Education

3. Skelton’s Recommendations for Educational Programs
Limit the length.
Fit the format to the preferred way of learning.
Meet patients where they are in regard to treatment
options and knowledge.
complex issues in easy-to understand language.
• Explain
the amount of information presented at one time
• Lessen
(chunking).

•
•
•

Published by MaineHealth Knowledge Connection, 2019

Conclusions

•
•
•

•

Needs assessment revealed many problems
and corrective measures to improve patient
education.
Nationally, there is a huge effort to improve
patient education, given the prominence of
kidney disease and the long wait for
transplants.
Alternative Pathway for Education prototype
will undergo future refinement but contains
essential elements for improved education:
limited length, prioritizing SSM and TTM
models, chunking of information.
Hand-outs are in the process of a healthliteracy evaluation for better
understandability.

SSM and
TTM
Additions in
Introductory
Module
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A Comparison and Analysis of C2 Nerve Root Sacrifice Technique with Clinical Outcome
Emma C. England, Jeffrey E. Florman MD; Deborah A Cushing RN
Department of Neurosurgery, Maine Medical Center

Methods

Abstract
The C2 nerve occupies a challenging anatomical
position when inserting C1 lateral mass screws
during atlantoaxial fixation and often requires root
sacrifice or retraction. The method for C2 nerve
sectioning is a potentially modifiable factor
influencing clinical outcome and incidence of
occipital neuralgia (ON). In this series, C2 nerve
transection is performed routinely and clinical
outcomes were assessed prospectively.

Introduction
Table 1. Review of C2 Nerve Root Transection Techniques
Study &
Year
Aryan
(2008)

Cauterization

Sectioning
Location

ON (95% CI)

bipolar
electrocautery (EC) proximal to the
with metzenbaum DRG
scissors

1 of 102
(p=0.010)

mid-portion of
C2 articulation

0 of 14
(p=0.000)

mid-portion of
C2 articulation
proximal to the
DRG (or
through the
DRG)

0 of 19
(p=0.000)

Squires and
Molinari monopolar EC
(2010)
Kang et al bipolar EC with
(2012) Malis scissors
monopolar EC;
Yeom et al bipolar EC & knife
(2013) or metzenbaum
scissors

Methods

6 of 24
(p=0.250)

Table 1. An overview of literature describing C2 sectioning
technique and location for patients who underwent sacrifice
with follow up.
vertebral artery

lateral mass

Figure 1&2. Demonstrate the complex anatomy relevant to
atlantoaxial fusion including the C2 nerve which is sacrificed
in this cohort of patients.

• Literature was reviewed in attempts to compare the described
sacrifice techniques (Table 1).
• Inclusion of trauma patients requiring C1-2 fusion and C2 nerve
root sacrifice between 2007 and 2017
• All of the patients charts were reviewed with attention ON
incidence, narcotic use and numbness dictated in the to postoperative office visits by the surgeon.
• The routine C2 sacrifice method was described in detail by the
surgeon.
• Telephone interviews were conducted using
the American Chronic Pain Association (ACPA)
scale to assess quality of life, and the International
Classification of Headache Disorder (ICHD-3)
scale to assess headaches and neck pain.

Discussion
• C2 nerve root sacrifice is often used to minimize
blood loss, operating time, risk of injury to the
vertebral artery, and increase visibility.
• Literature review reveals minimal but variable
description for cutting the nerve.
• The C2 sacrifice technique in this series is most
comparable to that described by Kang et al (2012).
• 0 of 35 patients have symptoms consistent with ON
at 3 month f/u with the surgeon
• 4 of 17 patients admitted to head/neck pain
consistent with ON during delayed phone f/u
• 1 of the 4 patients was taking narcotics for head pain

• It proves difficult to correlate sacrifice
technique to occurrence of ON

Figure 3. Demonstrates the portion of the head effected by the C2 nerve.
“A Variation of Type III Odontoid Fracture As Isolated Jaw Pain” By M Walid et. al.

Results
66 C2 nerve roots were divided at the mid-portion of the C1 lateral
mass using bipolar electrocautery. There were no instances of
vertebral artery injury, transfusions, or CSF leakage.
Table 2. Results from early office visits and delayed follow up
# of
Occipital Narcotics for Type of
# Nerves Time Range
Patients
Pain
head pain? Narcotic
Early f/u
1-7 months
Office
35
66
0
0
n/a
(mean=2.7)
Visits
Delayed
0.5-4 years
liquid
Phone
17
31
4 of 17
1 of 17
(mean=2.2)
morphine
Survey
Table 2. Displays incidence of ON reviewed at the two f/u stages.
Table 3. Results from delayed follow up patients
Severe Neck Severe Headaches Occipital
QOL ≥ 6
( ≥ 3)
Pain
Pain ( ≥ 3)
# Effected
3 of 16
1 of 16
4 of 17
14 of 17
Table 3. Breaks down the responses from the 17 patients with delayed f/u
using the ACPA and ICHD-3 scales.

https://knowledgeconnection.mainehealth.org/jmmc/vol1/iss1/16
DOI: 10.46804/2641-2225.1017

Learning Objectives
1.
2.
3.

C2 nerve root sectioning technique is poorly
understood
C2 nerve root sacrifice has excellent long term
outcome
Transection technique may influence clinical
outcome
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Characterization of a Novel Mouse Model with Adipocyte-specific Transgenic Expression of Mesoderm Specific Transcript
Gary R. Kersbergen, Rea Anunciado-Koza and Robert A. Koza
Adipose-specific inactivation of Mest

Abstract

Mice with an adipose tissue specific inactivation of Mest created by crossing mice with a paternal
floxed allele for Mest with Adipoq-cre transgenic mice reduced bodyweight gain and adiposity
compared to littermate controls after being fed a high fat diet from 8 to 24 weeks of age.

Methods

Introduction
CAG-GFP-Mest

Epigenetics & Obesity
CAG-cre-

a

Tissues from transgenic mice were harvested and analyzed for Mest expression by qRT-PCR. Gene
expression was measured in arbitrary units (AU) and normalized to TBP. Some founder lines were found
to be more effective at overexpressing Mest than others .

b

Gonadal WAT Founder Line
U22/SLA

c

d

mRNA (AU/TBP)

HIGH FAT DIET

Cre+ (n=4)
5

20

Experimental Design
A tissue specific transgenic
model was created using a
CAG promoter with GFP
inserted between two LoxP
sites. When crossed with a
cre recombinase mouse, the
GFP between LoxP sites
was removed resulting in the
CAG promoter functioning to
overexpress Mest. A
conditional trasgenic model
and a Mest-Myc fusion
protein model were made
using this method.

Cre- (n=4)

15
10
5
0

Cre- (n=4)
Cre+ (n=4)

5

0

0

Transfection of HEK293 cells CAG-GFP-Mest and CAG-GFP-Mest-Myc (A,B) and co-transfection of
cells with CAG-cre recombinase (C,D) resulted in reduced GFP signal for CAG-GFP vectors. Cells
were quantified by qRT-PCR.

Inguinal WAT Founder Line
U22/SLA
10

mRNA (AU/TBP)

10

CAG-cre+

Epigenetics is defined as the
study of how changes in an
organism’s physical or
nutritional environment initiate
biological mechanisms that
bring about changes in gene
expression, but not the
underlying DNA sequence.
Using an inbred, genetically
identical, mouse strain, our lab
seeks to understand the
biological mechanisms and
genes that function as
epigenetic regulators for
variable development of dietinduced obesity. To characterize
these epigenetic regulators,
inbred mice were fed a high fat
diet in a controlled environment
to identify genes associated
with variable body weight
among individuals. Mest, an
imprinted gene has been shown
to be strongly correlated with
increased body weight and fat
mass gain.

CAG-GFP-MestMyc

mRNA (AU/TBP)

Mesoderm Specific Transcript (Mest) is expressed variably among genetically homogeneous mice and highly induced
in adipocytes when mice are fed an obesogenic diet. The correlation of elevated Mest expression to increased body
weight and fat mass gain implicate Mest as a potential epigenetic regulator of diet-induced obesity. In order to
understand the regulation and function of Mest, a conditional transgenic model was created using Mest driven by a
CAG promoter which can be activated by tissue-specific expression if cre-recombinase. Transgenic mice were placed
on a chow diet and the organs and fat pads were harvested. RNA was isolated from these tissues and analyzed by qRTPCR in order to confirm that the transgenic model was tissue specific. qRT-PCR analysis demonstrated that Mest
transgenic mice expressing Adipoq-cre positive mice resulted in the induction of Mest in adipocytes at a level
consistent to mice fed a high fat diet. Previous studies have shown that endogenous Mest is co-regulated with several
genes including imprinted genes (Klf14) and genes associated with the Wnt (Sfrp5) and Tgf-B (Bmp3) signaling
pathways. Using a transgenic model, we were able to confirm that Mest expression plays a role in regulating the
expression of Sfrp5 in gonadal adipose tissue and brown adipose tissue, but not in inguinal adipose tissue. Slc5a7, a
gene shown to be dowregulated in gonadal adipose tissue of Mest knockout mice was also shown to be up-regulated in
mice overexpressing Mest . These studies show that this transgenic model will allow us to better understand the
biological mechanism by which Mest functions as an epigenetic determinant of diet-induced obesity.

Brown Fat Founder Line
U22/SLA
Cre- (n=4)
Cre+ (n=4)

Gene expression was
measured in arbitrary
units (AU) and
normalized by TBP. We
determined that mice
with transgenic
expression of Mest also
showed elevated levels
of Sfrp5 and Slc5a7 in
gonadal fat and in brown
fat only, and lower levels
of Ucp1 that was most
evident in gonadal fat.

Summary/Conclusions
To better understand the function and regulation of Mest in adipose tissue expansion, we generated a conditional
CAG-GFP-Mest transgenic mouse model that overexpresses Mest only in adipose tissue.

Results

• Analysis by qRT-PCR revealed that Mest overexpression in the transgenic model was specific to adipocytes and
that it was at a level consistent with HFD-induced wild type Mest expression in inguinal and gonadal fat.
• Expression of Sfrp5, and Slc5a7 was elevated in gonadal fat and brown fat, but not in inguinal fat. This increase
was significant in Sfrp5 and Slc5a7 (p < 0.005) in brown fat, and in Slc5a7 (p < 0.05) in gonadal fat.
• Mest transgenic mice also tend to have reduced expression of Ucp1 in gonadal and brown adipose tissue.
These results suggest that Mest, or the consequence of elevated expression of Mest, plays some role in the
function and regulation of several adipose genes such as Sfrp5, Slc5a7 and Ucp1. Further studies using a larger
pool of age-matched mice and various dietary conditions, as well as mice with inactivation of Mest, will be valuable
in determining how transgenic overexpression of Mest effects adipose tissue function.
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Podocalyxin Promotes Activation of STAT3 Signaling Pathway in Emergency
Granulopoiesis
Jahanara Freedman1,2, Aldona Karaczyn1 and Pradeep Sathyanarayana1
1Center

for Molecular Medicine, Maine Medical Research Institute, Scarborough, Maine 2 Wellesley College, Wellesley, Massachusetts

Results

Abstract
Background:

Neutrophils serve a critical function in the innate immune system by
maintaining a frontline defense against bacterial and fungal pathogens. New generations of
neutrophils as a result of increased myeloid progenitor cell proliferation in bone marrow in
response to severe infection is called emergency granulopoiesis. To maintain healthy
neutrophil numbers, the process of granulopoiesis is tightly regulated. Granulocyte colonystimulating factor (G-CSF) is a hematopoietic growth receptor that is the primary stimulator
for neutrophil production during emergency hematopoiesis. Janus kinase, signal transducer
and activator of transcription (STAT) pathway components are principle intermediates in the
G-CSF receptor signaling cascade. Jak2 is one of the key downstream kinases stimulated
by G-GCSF. Once phosphorylated, Jak2 activates STAT3 to be transported to the nucleus: a
cascade necessary for accelerating neutrophil production. During G-CSF-driven emergency
granulopoiesis, STAT3 is required to boost immature neutrophil numbers in bone marrow
and to regulate acute neutrophil mobilization.

A]

*

Rationale: The signal transduction pathways that regulate emergency granulopoiesis are of
significant interest as G-CSF is used therapeutically to increase circulating neutrophil counts.
However, the underlying mechanisms directing G-CSF-responsive myeloid progenitor
expansion are poorly understood.
Podocalyxin is a transmembrane protein belonging to the CD34 family, and is widely
expressed in hematopoietic cells. Previously, our laboratory discovered that mice lacking
Podocalyxin (Podxl) had significantly elevated peripheral blood neutrophils following G-CSF
treatment. Therefore, the long-term goal of this project is to understand how Podxl regulates
granulopoiesis and functional maturation of neutrophils in bone marrow. In this study, we
investigated whether loss of Podxl affects i) basal activity of STAT3 in myeloid progenitors,
and ii) activity of STAT3 in the emergency granulopoiesis due to response to G-CSF
administration.
Experimental Strategy: Mice, lacking the Podxl gene in their hematopoietic cells, were used
in this study. Effects of Podxl deletion on myeloid progenitor (GMP) cell production during
homeostasis and G-CSF-driven emergency response were assessed. Flow cytometry
analyses were applied to investigate phosphorylated levels of STAT3 in GMPs from wildtype
(WT) and Podxl conditional hematopoietic knock-out (cKO) mice injected with PBS or GCSF.
Results: We found that loss of Podxl reduces activity of STAT3 during emergency
granulopoiesis and homeostasis. These results coincided with reduced number of the GMP
population in both Podxl cKO mice injected with G-CSF and those injected with PBS,
suggesting that Podxl deletion restricts GMPs’ differentiation.
Conclusions: Podxl promotes positive effects of STAT3 in the granulocytic lineage that directs
G-CSF-responsive myeloid progenitor proliferation.
Future Studies: We hope to investigate whether i) loss of Podxl affects myeloid progenitor’s
cell-cycle progression and maturation in response to G-CSF, and if ii) Podxl regulates
neutrophil trafficking during emergency granulopoiesis.

Figure 4: Loss of Podxl reduces activity of STAT3 signaling during homeostasis and G-CSF- induced
emergency granulopoiesis. The same experimental and data analysis approach and gating strategy was used
as described in Figure 3. Anti-STAT3, phospho-STAT3 PE and isotype control antibodies were also used.
Statistical significance was performed using the Student’s Two-Tailed T-Test for Significance. *p<0.05 **p<0.01
***p<0.001. (N=4, N=8, N=8).

B]

Discussion and Conclusions
We found that absence of Podxl in GMPs reduces activity of STAT3 on basal level and in G-CSF-induced
response. This negative effect of Podxl deletion on STAT3 phosphorylation coincided with markedly reduced
number of GMPs. We found no difference in the total level of STAT3 in G-CSF-treated Podxl cKO as compared
to wildtype mice, however total levels of STAT3 were increased in Podxl cKO in steady-state, suggesting an
existence of regulatory feedback. Studies have shown that in steady state, STAT3 serves a negative regulatory
function by suppressing accumulation of neutrophils in blood1. This activity is attributed to STAT3-dependent
regulation of a feedback inhibition of G-CSFR signaling. We recently found that Podxl deletion increases
accumulation of the immature myeloid subpopulation with the associated drop in mature neutrophils in the bone
marrow, and increased levels of neutrophils in blood. We found that Podxl-deficient GMPs showed suppressed
G-CSF–responsive growth relative to wild-type cells, however the underlying cellular response such as
enhanced rate of differentiation of GMPs remained unclear. To conclude, our findings suggest that Podxl
promotes the activation of STAT3 in the granulocytic lineage that directs G-CSF-responsive myeloid progenitor
proliferation. In the future, we hope to explore the effects of the loss of Podxl on myeloid progenitor’s cell-cycle
progression and maturation in response to G-CSF. We also hope to investigate if Podxl regulates neutrophil
trafficking during emergency granulopoiesis.

**

Figure 2: G-CSF induces GMP proliferation and STAT3 activation in vivo. Lineage negative c-kit positive,
Sca-1 negative compartment (KL) containing myeloid progenitors from wildtype mice injected with either G-CSF
or PBS, N=4. To characterize GMP population, CD34 and CD16/32 antibodies were used. GMP compartments
were further analyzed to show expression of phosphorylated STAT3 [A] or un-phosphorylated STAT3 [B]
expression between groups. Anti-STAT3-PE, phospho-STAT3 PE and isotype control-PE antibodies were also
used. Plots were collected using FlowJo. Statistical significance was performed using the Student’s Two-Tailed
T-Test for Significance. *p<0.05 **p<0.01 ***p<0.001.

Methods
We used Podxl conditional knock out (cKO) mice model generated using the flox-Cre technique to
delete the expression of Podxl in hematopoietic lineages. Wildtype and Podxl cKO mice were
injected with 125 µL/g G-CSF twice in two days to induce emergency response in hematopoietic
system. Initially, induction of myeloid progenitors (GMPs) were tested in wildtype and wildtype GCSF treated animals. Tested groups included wildtype(WT),
wildtype with G-CSF(WT G-CSF), Podxl cKO(cKO), Podxl
cKO with G-CSF(cKO G-CSF). Bone marrow(BM) from the
tibias and femurs was collected. BM cells were flushed with
IMDM medium supplemented with 2% FBS and antibiotic
and centrifuged. BM cells were passed through 21G syringe
and 0.45 micron strainer. 0.5% Bovine Serum Albumin
buffer and PBS 1x was added to the cells to be centrifuged.
Cells were counted using hemocytometer. Red blood cells
were removed by chemical lysis. Single cell suspension of
BM cells was processed by EasySep Mouse Hematopoietic
Progenitor Cell Isolation Kit according to manufacturer’s
Figure 1: Flowchart diagram portraying
protocol (StemCellTechnologies). Lineage negative populaexperimental design

tion was obtained using immuno-magnetic separation. Number of lineage negative cells was
evaluated. One million cells were blocked with rat and rabbit IgG and labelled by antibodies(C-kit,
Sca1, CD16/32, CD34) followed by fixation and permeablization. Phospho-STAT3, STAT3, and
isotype IgG antibodies were added separately to tested groups and incubated for one
hour. Samples were submitted to flow cytometry for analysis. Flow cytometry data analysis was
performed using FlowJo.

A]

B]

Figure 5: Model of Podxl’s role in G-CSF induced Emergency Granulopoiesis. Upon G-CSF (left panel),
Podxl is hypothesized to promote Jak2/STAT3 pathway. Jak2/STAT3 pathway consists of intracellular signaling
cascades that control demand-driven neutrophil production. Briefly, G-CSF phosphorylates transmembrane
protein Jak2 which then phosphorylates STAT3. Newly activated STAT3 enters nucleus to activate transcription
factors to promote reactive granulopoiesis, leading to production of neutrophils. Podxl’s absence in hematopoietic
systems (right panel) leads to decreased GMPs production in bone marrow, with concomitant drop in mature
neutrophils (data not shown). Loss of Podxl results in elevated accumulation of neutrophils in blood. The reason
for the increase in neutrophil levels in the absence of Podxl during GCSF-induced response remains to be
elucidated.
Figure 3: Loss of Podxl reduces frequency of GMPs during homeostasis and G-CSF-induced stress
granulopoiesis. A] Representative gating strategy of lineage negative c-kit positive Sca-1 negative
compartment containing myeloid progenitors and subsequent characterization of GMP population between Podxl
cKO and WT mice treated with either PBS or G-CSF. In bone marrow, lineage negative population, c-kit, and
sca-1 were used to identify myeloid progenitor compartment, and CD34 and CD16/32 antibodies were used to
identify GMP populations. Experiments were performed three times. (N=4, N=8, N=8). Both plots were collected
using FlowJo. B] Frequency of GMP population between Podxl cKO and wildtype mice treated with either PBS
or G-CSF. Statistical significance was performed using the Student’s Two-Tailed T-Test for Significance. *p<0.05
**p<0.01 ***p<0.001
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Relationship Between Travel Distance to Cancer Care Center
and Outcomes in Ovarian Cancer
Jonathan Emery, Lee Lucas PhD, Leslie Bradford MD
Aim

The purpose of this investigation is to determine whether there is
an association between proximity of patients to a comprehensive
cancer center and mortality in ovarian cancer patients.

Study Variables

PREDICTIVE VARIABLE:

Characteristic

Travel Distance

NCDB includes a variable,
CROWFLY, which is an
estimation of the distance
between the ZIP code of the
patient’s residence and the
facility. In this analysis, we split
the travel distance into
quartiles so that about 25% of
the patients were within each
distance range as follows:
Q1: < 5.2 miles
Q2: 5.2 – 11.9
Q3: 12 – 31.1
Q4: > 31.1

Introduction

In 2015, there were 1.2 million women with ovarian cancer, which
resulted in 161,100 deaths worldwide. Ovarian cancer is the
seventh-most common cancer, and the eighth most common cause
of death from cancer. In Maine, 14,070 women are expected to die
from this disease in 2018.
There is evidence that high volume facilities produce better
outcomes for patients. This has led to an argument in favor of the
regionalization of medical facilities. A possible drawback of this
strategy is an increase in travel distance for patients. To begin
weighing the pros and cons of regionalization it is worth asking:
Does travel distance affect mortality?

Methods

Data from 2004 through 2015 were abstracted from the National
Cancer Database (NCDB), a nationwide oncology registry with
information on more than 70% of incident cancers in the United
States. The study cohort included 165,674 patients and were
limited to those with an invasive diagnosis, treated at a reporting
facility, and not missing data for travel distance or stage.

Exclusion Criteria
National Cancer Database
Ovarian cancer instances
2004-2015
(N=194,828)

Baseline Characteristics of Cohort

OUTCOME VARIABLE:

30 Day Mortality

NCDB includes a binary variable,
which tells whether a patient has
died 30 days after their diagnosis.

Covariates
-

Age
Race/Ethnicity
Stage
Comorbidity score
Type of Cancer Center
Income
Education
Insurance
Facility volume

Results
Multivariable logistic regressions were performed to obtain odds ratios for each category distance compared to
the first quartile (Q1) as reference. Before controlling for covariates we saw significantly lower odds of mortality
with longer travel distances. Without covariates we found: Q2 Odds Ratio (OR), 0.884 [95% CI, 0.788 to 0.991],
Q3 OR, 0.724 [95% CI, 0.643 to 0.816], Q4 OR, 0.891 [95% CI, 0.797 to 0.997].
With covariates, we lost some of these significant odds ratios: Q2 OR, 1.042 [95% CI, 0.925 to 1.175],
Q3 OR, 0.881 [95% CI, 0.777 to 0.999], Q4 OR, 0.952 [95% CI, 0.841 to 1.077].

Non-invasive ovarian cancer
(N=1,151)

Age
< 40
40 - 49
50- 59
60 - 69
70 - 79
> 80
Charlson-Deyo score
0
1
>2
Insurance
Uninsured
Private
Medicaid
Medicare
Other
Median income in patient’s ZIP code
< 38,000$
38,000$ - 47,999$
48,000$ - 62,999$
> 63,000$
No high school degree in patient’s ZIP code
> 21%
13% - 20.9%
7% - 12.9%
< 7%
Facility Type
Community Cancer Program
Comprehensive Community Cancer Program
Academic/Research Program
Integrated Network Cancer Program
Rurality
Metro
Small Urban
Rural
Isolated Rural
Stage
1
2
3
4
Mean facility volume per year
< 11.6
11.6 - 25.08
25.09 - 39.67
> 39.67

1st
quartile
(n =
41,446)

4th
quartile
(n =
41,390)

2509 (6)
2565 (6)
4887 (12) 5177 (13)
9054 (22) 10420 (25)
9570 (23) 11601 (28)
8551 (21) 8294 (20)
6875 (17) 3333 (8)
32243 (78) 33496 (81)
7048 (17) 6268 (15)
2155 (5)
1626 (4)
1706 (4)
1756 (4)
17480 (42) 18507 (44)
3093 (7)
2571 (6)
18271 (44) 16705 (40)
259 (1)
545 (1)
8115 (20)
9017 (22)
10289 (25)
13997 (34)

10179 (25)
14017 (34)
10771 (26)
6345 (15)

7497 (18)
9122 (23)
13026 (31)
11186 (27)

8388 (20)
13037 (32)
13729 (33)
6197 (15)

3906 (10)
715 (2)
17852 (46) 13412 (35)
12849 (33) 21203 (55)
4330 (11)
3495 (9)
39334 (97) 21703 (54)
1043 (3)
6349 (16)
212 (1)
9915 (25)
5 (0)
2387 (6)
9920 (24) 9647 (23)
3715 (9)
3877 (9)
15902 (38) 19395 (47)
11909 (29) 8471 (20)
16634 (40)
11180 (27)
8414 (20)
5218 (13)

4600 (11)
8945 (22)
10515 (25)
17330 (42)

Chi-square
p-value
<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

Percent of Patients Treated at Each Type
of Cancer Center by Distance.

Odds Ratios
Q1 vs Q2

Invasive ovarian cancer
(N=193,677)
Patients treated in
non-reporting facility
(N=8,786)

Q1 vs Q2

Patients treated in
reporting facility
(N=184,891)

Q1 vs Q2
Patients missing stage
(N=16,805)
Patients missing travel distance
(N=2,412)

Final Cohort
(N=165,674)

Published by MaineHealth Knowledge Connection, 2019

Lower mortality

Higher mortality

Conclusion
After controlling for covariates, we can say that, overall, travel
distance does not have a statistically significant relationship with
30 day mortality among ovarian cancer patients. The next step,
for a more in depth look at this question, would be to examine
patients who travel further specifically to higher volume facilities
in comparison to those who travel shorter distances to lower
volume facilities and then to see if any effect is statistically and
clinically significant.
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Focality and Co-infection of Powassan Virus (Lineage II) within a Population of Ixodes
scapularis Ticks in Wells, ME
Keenan Ernste, Kyle Timmer, Rebecca Robich, Susan Elias, Charles Lubelzcyk, Elisabeth Henderson, Danielle Cosenza, Margaret Welch, Robert Smith
Vector-Borne Disease Laboratory – Maine Medical Center Research Institute

Background

Methods

Powassan virus (Flaviviridae: Flavivirus) is a vector-borne
disease that circulates in parts of North America and Russia in
two serologically-indistinguishable lineages: lineage I (POWV)
and lineage II (deer tick virus [DTV]). This study looked at DTV.
• Recent evidence suggests DTV may exhibit nidality, meaning
it exists in small microhabitats (foci) consisting of just the right
mixture of environmental factors for the virus to propagate.2
• Exists primarily in a zoonotic cycle between Ixodes
scapularis ticks (deer ticks) and small-medium mammals (e.g.
the white-footed mouse, woodchucks, and skunks).7
• ~10% of POWV human infections result in deadly encephalitis
and 50% result in long-term neurological sequelae.7
• In the United States there has been a threefold increase in
human infections in the past two decades (27 cases from
1958-1998 and 85 cases from 2003-2017), which may be due
to rising deer tick populations in parts of North America.5,7
• Ticks can be co-infected with other vector-borne diseases
such as the agents of Lyme, anaplasmosis, babesiosis, and
tick-borne relapsing fever.1
More southern counties in Maine reportedly have higher DTV
infection rates compared with those in the north. This study was
conducted in York County, which had an adult deer tick infection
rate of 2.27% in the fall of 2017.

Field Collection
• Flagged for ticks in ten transects (5 different habitat types) in
the Wells National Estuarine Research Reserve in Wells,
ME. Each transect made up of ten consecutive 10x1m plots.
1. Forest with invasive shrub species in the understory
2. Forest with sparse, native shrub species in the Understory
3. Edge (forest-field intersection)
4. Shrub (little-to-no tree cover)
5. Field (grassland)

1999-2017

2016

Results

The majority of nymphal and adult ticks were collected from a
deciduous forest habitat with an understory mostly composed of
invasive species of plants
Ticks per Hour by Cover Type, WNERR, 2018
70
Ticks Per Hour

60
50
40
Adults
Nymphs

30
20
10
0

Forest with
Invasive
Understory

Edge (Forest- Shrub (little-toForest with
no Tree Cover)
Field
Sparse, Native
Intersection)
Understory

Field
(grassland)

Habitat Cover Type
Fig. 3: Bar graph showing the number of ticks/hr by habitat type. The most adults and nymphs
were collected from the forested habitats with invasive shrub species in the understory

Fig. 2: Left image is an example of the flagging procedure for tick collection.
The right image shows female (F) and male (M) adult deer ticks

Laboratory Testing
• Ticks were ground in PBS solution and aliquots of these were
tested in pools (10 adults/pool, 20 nymphs/pool, and 50
larvae/pool) by RT-PCR, amplifying the NS-5 gene (806bp).
• Individual ticks from positive pools were then tested using the
same RT-PCR protocol and any positives were confirmed by
genomic sequencing
• To determine rate of co-infection, DTV-positive ticks were
then tested for B. burgdorferi, A. phagocytopylum, B. microti,
and B. miyamotoi by PCR assay.

An ArcGIS hotspot analysis tool identified, with 99% confidence,
that areas within transect 3 (forest with invasive shrub species
in the understory) may have been “hotspots” (focal transmission
sites) for DTV.4

7
8
10

6
9

5

Results

Objectives
• Investigate nidality by collecting ticks from five different
habitat types and testing them for DTV to determine what
constitutes a good pathobiocenose.
• Determine what percentage of DTV-infected ticks were
also infected with Lyme, anaplasmosis, babesiosis, and/or
tick-borne relapsing fever.

Hypotheses
• DTV-infected ticks will exhibit nidality (focality), meaning
they will tend to exist within certain microhabitat-types
more than others.
• Co-infection will be observed in ticks infected with DTV.

Habitat Type

Transect 1

Brush

Transect 2
Transect 3
Transect 4

Forest with Invasive
Understory

Transect 5

Field

Transect 6
Transect 7

Forest/Edge

Transect 8
Transect 9
Transect 10

Forest with Native/
Sparse Understory
Total

https://knowledgeconnection.mainehealth.org/jmmc/vol1/iss1/16
DOI: 10.46804/2641-2225.1017

Number of
Ticks (%)

Number of DTV
Positives

23 (6.2)

1

2 (0.5)

0

106 (28.4)

6

113 (30.3)

2

6 (1.6)

0

10 (2.7)

1

14 (3.8)

0

21 (5.6)

0

67 (18.0)

0

11 (2.9)

0

373

10

• The habitat type in which the most ticks were collected,
deciduous forest with invasive shrub understory, is
consistent with previous research.8 This is thought to be
because some invasive shrub species are resistant to deer
browsing, act as good habitats for small mammals, and
provide shade for ticks6.
• Our reported 2.7% infection rate is within the 0.6-5% range
expected from previous reports.3 The actual infection rate
may be higher because this study primarily took place
during peak nymphal season, and nymphs may have lower
infection rates than adults (unpublished data).

• The 70% positivity rate for DTV and B. burgdorferi (Lyme)
co-infected ticks corresponded with reports on Lyme
infection rates in Wells, ME (annual CDC report 2012).
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Table 1. Field Site Characteristics and Collection Results
Transect Number

• This novel finding indicates possible nidality (focality) for
DTV that corresponds with habitats known to be favorable
for deer ticks (i.e. deciduous forest with invasive shrub
species in the understory). Therefore, invasive shrubs, like
barberry, may play a role in forming DTV-favorable
pathobiocenoses. However, differences in sample sizes
between transects means we need to exercise caution
when extrapolating this data.

• Also similar to previous reports, only lineage II (DTV) and
not lineage I (POWV) was found in I. scapularis ticks.2,3,7

Out of 373 total ticks tested, 10 adults were positive for DTV,
making the overall infection rate 2.7%. Eight of the positive
ticks came from a deciduous forest habitat with invasive plant
species, namely Japanese barberry, in the understory.
Fig 1: Left image is a map of human POWV/DTV infections in Maine
and the right image is showing prevalence of POWV-infected deer ticks

Discussion

This study investigated Powassan virus nidality and coinfection within Ixodes scapularis ticks in Wells, ME by
collecting 373 ticks and using PCR assays and genomic
sequencing to test for DTV. Positive ticks were also tested for
co-infection with B. burgdorferi, A. phagocytophylum, B.
microti, and B. miyamotoi.
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Fig. 3: Hotspot analysis of transects. Transects are numbered and dots represent
plots within transects. The red dots from transect 3 indicate hotspots identified with
99% confidence and white dots indicate plots that were not identified as hotspots

Co-infection PCR assays revealed that seven out of the ten total
DTV-positive ticks (70%) were also infected with B. burgdorferi
(Lyme). None of the DTV-positives were also infected with A.
phagocytophylum, B. microti, or B. miyamotoi.
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Characterization of the Proteolytic Processing of CTHRC1

Kimberly L. Drew1, Qiaozeng Wang MS1, Yong-Ri Jin PhD1, and Volkhard Lindner MD,PhD1
1Center

for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine
Results:

Introduction:
Collagen Triple Helix Repeat Containing 1 (CTHRC1) is a hormone that is
currently being researched in the biomedical field for its role in a variety of
different health interests, including, but not limited to cancer, heart disease,
inflammatory response, metabolism, bone growth and aging1,2,3. As CTHRC1 is
a versatile hormone, the proteolytic processing of this hormone, and where it
is active and secreted are essential information to be able to use CTHRC1 to
further the understanding of its role in these complex medical interests. The
proteolytic processing of CTHRC1 is not clearly understood, specifically
whether or not the hormone needs to be activated and if it does; how it is
activated and secreted. CTHRC1 is expressed in neuroendocrine cells, which
require regulated secretion to be activated and this led to further conclusions
that CTHRC1 might require activation and regulated secretion as well. As
CTHRC1 has a c-terminal lysine, literature on the POMC processing pathway,
which involves carboxypeptidase E (CPE) cleaving the c-terminal lysine, gave
way to a possible mechanism that could be explored to understand the
proteolytic processing of CTHRC14,5. To characterize this possible mechanism,
six cell lines were transfected with four different plasmids, and the
conditioned medium and cell lysate were immunoblotted to observe
secretion, possible truncations to the hormone, and presence of
CTHRC1. These cell lines were also immunoblotted for endogenous CPE,
resulting in two further experiments to understand the impact of CPE, these
included: observation of cell line that expressed endogenous CPE (AtT20) and
the second being the observation of one that does not (293-T) to understand
the ways that CPE influences secretion in these cells.

Figure 1. Schematic of the POMC processing pathway
in the hypothalamus from Bicknell et all.5
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Figure 5. 293-T cells transfected with hFL show
minimal secretion of CTHRC1. Transfection of 293-T
Figure 4. 293-T cells transfected with rFLmychis show
cells with plasmid hFL as indicated and those with
secretion of CTHRC1. Western blotting of the
plasmid GFP as a control were harvested as
conditioned medium (CM) and the cell lysates (CL) of
conditioned medium (CM) and cell lysate (CL)
transfected cells with plasmid rFLmychis as indicated
samples. The membranes were probed with
and those with plasmid GFP as a control. These
various CTHRC1 antibodies, which indicated some
samples were probed with various CTHRC1
secretion of CTHRC1 into the CM, as well as high
antibodies, as indicated on the side of each blot.
prevalence in the CL. The control indicates nonSeveral of the blots show the secretion into the CM,
specific bands that are around 30 kDa as well,
as well as two bands in the CM, which shows a fully
although the strength of the band differs and does
post-translationally modified sample as well as that
not conclude that these bands are nonspecific in
which has not been fully modified.
the hFL transfected samples.

The POMC processing pathway
occurs in the hypothalamus and
the pituitary and is an essential
pathway in the creation of ACTH
and alpha MSH.4,5 In this pathway,
there is the cleavage of the cterminal lysine from the hormone,
which is a possible mechanism for
the activation and secretion of
CTHRC1. As CPE is expressed in the
pituitary, and CTHRC1 is as well, this
appeared to be a possible
candidate for the cleavage, and
ultimately secretion and activation
of CTHRC1.6,7

kDa
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α-10G7

46--

Figure 9. Mouse brain, bone and joint, heart,
and cortical have high expression of
CPE. Results from qRTPCR detail a high
expression of CPE in the mouse brain, as
expected, as well as fairly high levels in the
mouse bone (includes joint and
cartilage). There is also a high level of
expression in the mouse heart and
cortical(without bone marrow). The mouse
embryonic fibroblast, endothelial cells, and rat
CAT (carotid artery injury vessel), have low
expression, with the mouse tibia (without bone
marrow) resulting in the lowest
expression. These results correlate with known
research on the location of CPE, with notably
high amounts in the mouse brain.

Figure 10. Expression of CPE is
significantly higher in human smooth
muscle cells compared to human
endothelial cells. This qRTPCR data shows
a high level of expression of CPE in the
smooth muscle cells and a minimal
amount in the human endothelial cells.
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75-46--

α-13E9
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Figure 6. Transfected AtT20 cells that express CPE endogenously indicate modification between cell lysate
and conditioned medium. Western blotting of transfected AtT20 cells with hFL, hFLΔK, VVD, and CTHRC1 7his
plasmid samples conditioned medium (CM) and cell lysate (CL), indicates minimal detection of CTHRC1
around 30 kDa aside from the hFLΔK transfected cells. These samples indicate a shift in the CTHRC1 samples
along the membrane in the CL and CM, which could be explained by the presence of CPE(expressed
endogenously). The controls indicate nonspecific bands that are similar to the bands that show the presence
of CTHRC1, which makes it difficult to read.

13E9 detects an unknown epitope
between the N terminus and C
terminus

Summary and Conclusions:

Results:

Figure 11. Carboxypeptidase E (CPE) is endogenously
expressed in AtT20 cells. Western blotting of cell
lysates of all six cell lines not transfected and probed
with anti-carboxypeptidase E antibody shows a clear
detection of CPE around 50 kDa in AtT20 cells, a
minimal detection in NIH3T3 and EC cells, and no
detection in the remaining three cell lines.

Acknowledgements:

Figure 2. Schematic of CTHRC1 amino acids showing the CTHRC1 antibodies detections along
the protein.

Methods:

A

Transfection: The six cell lines were transfected with various plasmid using XTreme Gene 9
Transfection Reagent. The cells were transfected when they were around 50-70% confluent
for 72h before harvested. The plasmids used were:
- hFL ( human CTHRC1 full length)
- hFLΔK(human CTHRC1 without the terminal lysine)
- VVD (human CTHRC1 missing propeptide section of N-terminus)
- 502mychis (rat CTHRC1 with myc tag)
- CTHRC1 7his (human CTHRC1 with his tag)
Western blotting was completed using a 15% separating gel and 5% stacking gel, 15
microliters of each conditioned medium sample were loaded as well as 100 micrograms of
the cell lysate and were transferred to a Bio-Rad PVDF 0.2 millimeter membrane (A280
protein reading was used to determine the OD of each).

Results:

Figure 7. Cotransfection of 293-T cells with indicated plasmid and CPE does not appear to
secrete a higher amount of CTHRC1 in the conditioned medium. Most of the with CPE have
higher amounts of CTHRC-1 in the CM, although it is not a significant amount and in the case
of hFLΔK, that without CPE has a higher amount of CTHRC1 according to the OD450 read from
the plate reader than that with CPE.

B
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Figure 3 .293-T transfected cells portray CTHRC1 in the cell lysate and does not secrete into the
conditioned medium. Western blotting of transfected 293-T cells with four plasmid constructs hFL,
hFLΔK, VVD, and 502mychis, as well as the negative control of cells that were not transfected.
The conditioned medium (CM) and cell lysate (CL) were harvested, probed with the Vli55
antibody, and detects the presence of CTHRC1 around 30 kDa. The immunoblotting shows a
lack of secretion of the CTHRC1 into the conditioned medium, which could be due to the
nonexistence of CPE in the cells.

25--

α-Vli55

25--

α-13E9

Figure 8. 293-T cotransfected cells with CPE do not show clear secretion of CTHRC-1 into the conditioned
medium. Western blotting of cotransfected cells with plasmid CPE and indicated plasmid (hFL, hFLΔK, VVD,
502mychis), as well as plasmid EGFP and a second indicated plasmid as a control, were harvested in samples
of conditioned medium (CM) and cell lysate (CL). The probing of these blots with Vli55 and 13E9 as indicated
show that there is minimal secretion of CTHRC1 around 30 kDa into the CM as shown, and a continued
presence in the CL, with no clear increase with CPE. Note the shift between the CPE+ hFLΔK CL and EGFP+
hFLΔK that indicates a post-translational modification that is only occurring with CPE that is causing the sample
to move more slowly across the membrane. In the left blot, those cotransfected with hFL have the highest
secretion into the CM, notably that with CPE, although it is not as significant as expected. There is also a shift
between the 502mychis transfected cells that have the myc tag versus the plasmids that do not.
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1. 293-T cells do not secrete CTHRC1 efficiently, even with
the addition of CPE.
2. In the cell lysates, the lower, distinct band is the nonglycosylated version, whereas the fuzzy upper band is
the glycosylated version.
3. In the AtT20 and CHO cells transfected with hFL and
hFLΔK there was the indication of a slightly larger
band(s) in the conditioned medium of hFL and hFLΔK,
than that of the cell lysate. This indicates a further posttranslational modification that occurs outside of the cell
with these plasmids.
4. Depending on the cell line, the monoclonal CTHRC1
antibodies that were used show nonspecific bands that
are specific to that individual cell line.
5. In the AtT20 cell transfection Western Blot there is no
secretion outside of the cell especially with the
difficulties in reading the Western Blot due to the
nonspecific bands at a similar size, which was
unexpected. Assuming that there were no difficulties
with the transfection that indicates that this construct is
only minimally able to be secreted.
6. Previous results under mass spectrometry determined
that CHO cells CM has its c-terminal lysine, and so the
result of CHO not having expressed endogenous CPE
does not disprove the hypothesis.
7. Notably in the CHO transfection, the samples
transfected with 502mychis, show no shift between the
CM and CL. This may be explained by the c-terminal tag
influencing the post-translational modifications that take
place outside of the cell.
8. Along with this observation, the rFLmychis Western Blot
that exhibits the secretion of the CTHRC1 into the CM in
293-T cells may indicate that the c-terminal lysine
interferes with the ability for 293-T cells to secrete
CTHRC1 efficiently.
9. In the 293-T cells when cotransfected with CPE+hFLΔK,
the top band is significantly higher than that without CPE
and appears to be a trimer, which is unlikely after the
denaturing involved in Western blotting. This observation
currently does not have a conclusion aside from the
possibility that the trimer is covalently cross-linked, but will
continue to be explored in future experiments.
10. Mass spectrometry will be necessary to finalize these
observations in the future, as this will allow us to
determine where truncations are and whether or not it is
likely that this is caused by CPE.

Figure 12. Transfected CHO cells shows detection of CTHRC-1 in the cell lysate and some
conditioned medium, as well as the indication of a shift between the cell lysate and cell
medium. CHO cells transfected with the plasmids hFL, hFLΔK, VVD, and 502mychis as
indicated, and were collected as samples of conditioned medium (CM) and cell lysate
(CL) and the presence of CTHRC-1 was detected around 30 kDa. The membranes were
probed with various CTHRC1 antibodies. There are a series of shifts that are observed in
these cells, including that of the cells transfected with the plasmid that has the myc tag did
not migrate as quickly across the gel as the others, and those with the VVD plasmid that is
missing an epitope travels further. There is also another notable shift shown in the B)
diagrams in which there is a shift between the hFL and hFLΔK where the CM did not travel
as quickly as the CL and may indicate a possible modification during secretion.
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Genetic Testing in Hospitalized Children with ASD: Prevalence and Influences
Margaret Meserve1, Briana Taylor 1,2, Christine Peura1,2, Matthew Siegel1,2
for the Autism and Developmental Disorders Inpatient Research Collaborative (ADDIRC)

Introduction

Results

Results

 The American College of Medical Genetics,
American Association of Pediatrics, American
Association of Psychiatry, and other medical
governing bodies recommend that all children with
ASD are referred for genetic testing.1

Table 1: Demographic Characteristics of 729
Children with Autism Hospitalized in a Specialized
Inpatient Unit
Demographic

Genetic Testing
(N=314)

 Unfortunately, these clinical recommendations are
not reflected in practice throughout the ASD
population.1,2

Age (Years) (M/SD)

13.32 (3.45)

12.6 (3.34)

P = 0.204

Sex (Male) (N/%)

238 (75.7%)

350 (84.3%)

X2 = 8.36
p = 0.004

ADOS Module (N/%)
1
2
3
4

143 (45.5%)
44 (14%)
96 (30.5%)
31 (9.87%)

135 (32.5%)
40 (9.6%)
181 (43.6%)
59 (14.21 %)

65 (21.4%)
238 (78.5%)

103 (24.9%)
309 (75.1%)

38 (12.1%)

36 (8.67%)

186 (62.6%)
77 (25.9%)
34 (11.4%)

282 (72.3%)
94 (24.1%)
14 (3.5%)

 Children with ASD seeking care in inpatient
psychiatric units could benefit greatly from genetic
testing due to the complex natures of their
diagnoses and behavior, which often include lower
verbal levels, intellectual disability, self-injurious
behavior and emotional dysregulation.3

Objectives
 To examine the prevalence and findings of genetic
testing in an inpatient community of children
diagnosed with ASD.
 To look for potential factors within demographics,
medical history, family history and behavior that
could influence access, referral and reporting of
genetic testing.

Methods
 936 participants with ASD confirmed by direct
assessment using the Autism Diagnostic Observation
Schedule (ADOS) were recruited from the Autism
Inpatient Collection3, a study conducted in 6 child
psychiatric units in the US specializing in treatment
of ASD.
 207 were excluded due to missing information or
inconclusive data (N = 729).
 Parents filled out a Demographic and Medical Intake
Form at admission which included questions
regarding previous treatment, family history and
other medical history.
 Parents also filled out an Aberrant Behavior
Checklist – Community form at admission, scoring
their child on 5 subcategories of behaviors from 0 =
never a problem to 3 = severe problem.
 Bivariate logistic regressions were conducted to
examine the of parent reported genetic testing in
hospitalized children with ASD.

1

2

Parental Education
(N/%)
HS or Less
At Least Some College
Adopted (N/%)
Household Income
Less than $80,000
$80,000 - $160,000
More then $160,000

No Genetic
Testing
(N=415)

Results
c

Figure 2: Breakdown of the most common parent
reported genetic testing results.

Statistics

X2 = 21.63
p = 0.000



X2 = 1.22
p = 0.269

X2 = 2.30
p = 0.129
X2 = 17.44
p =0.000

 Of the total child sample, 588 (80.6%) were male and
the average age was 12.9 (SD = 3.3).
 436 (54.3%) children were non- or minimally- verbal
(determined by ADOS Module administered).
 There were statistically significant differences in
gender, ADOS module, and household income
between the two genetic testing groups
 Those with genetic testing were more likely to be
non- or minimally-verbal, and have a household
income of more than $160,000.

• 69.66% of parents with a significant result reported
that genetic testing resulted in some “other” finding
and 15.7% reported a Fragile X diagnosis.
• Of the Other results, 9.68% were disorders known to
have ASD etiology4 and 8.06% were considered ASD
candidate genes5.




Figure 3A-C: Health , Behavioral, and
Demographic Influences on Genetic Testing

Participants whose child was female were 71% more
likely to report genetic testing (p = 0.004).
Participants whose child was nonverbal (p = 0.005) or
minimally verbal (p = 0.018) were 201% and 209%
more likely to report genetic testing.
Families with an income of less than $80,000 (p =
0.00) or $80,000 - $160,000 (p = 0.002) were 72.8%
and 66.7% less likely to report genetic testing.

Conclusions
 Children seeking care in an inpatient psychiatric
facility received genetic testing at a higher rate than
the general ASD community(<40%), 1,2 although the
diagnostic yield for these tests matched the national
standards (10-40%).1,5

A

 Access to genetic testing and it’s findings could
greatly influence the course of care in this
population as it reveals important distinctions in
disorders and ASD subtypes.

Figure 1: The Rate of Genetic Testing Within an
Inpatient Population.

 These results suggest that family medical history,
child behavior, and demographic characteristics
predict likelihood of genetic testing. These
predictors may represent pathways or barriers to
access to referrals for genetic testing and follow
through by parents.

 Families with a history of bipolar disorder (p = 0.006)
were 74.1% more likely to report testing, while
families with a history of a genetic condition (p= 0.00)
were 78% times less likely.

B

 Further research is needed to understand the exact
pathways by which some families are referred and
receive genetic testing while others do not.
 43.07% of parents reported having genetic testing for
their child prior to their admission.
 25.6% received a significant result from this testing.
 A significant result consists of any disorder or
mutation found regardless of correlation to ASD.

3

4
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Physician-patient Communication About Genomic Tumor
Testing: Perceptions Of Oncology Providers
Alexandra McCown, Caitlin Gutheil, MS, Hayley Mandeville, MPH, Eric Anderson, Ph.D., Paul Han, MD, MA, MPH
Center for Outcomes Research and Evaluation (CORE) at Maine Medical Center Research Institute (MMCRI)

Abstract

Methods

Genomic tumor testing (GTT) is a potentially
• In April 2018, 76 physicians and clinical staff
valuable new technology that can make cancer
attended an annual 2-day MCGI conference,
treatment more “precise,” but there are
convened by JAX to educate and update
substantial uncertainties about its clinical value
providers on the progress of the initiative.
and appropriate use. Oncology physicians need • Conference participants were surveyed about
to counsel cancer patients about both the value
their beliefs and attitudes regarding GTT.
and uncertainties about GTT, but optimal
• Surveys consisted of both multiple-choice and
strategies remain to be determined.
open-ended questions, designed to assess
perceptions of the key goals and elements of
This study explored oncology providers’
physician-patient discussions of GTT.
perspectives on the essential content elements
•
Multiple-choice question (Key goals)
of physician-patient discussions about GTT. 76
“What do you think are the three (3) most
oncology providers who attended the annual
important goals when introducing GTT to a
meeting of the Jackson Laboratory’s Maine
patient?” (respondents chose from option list)
Cancer Genomics Initiative (MCGI) were
• Open-ended question (Key elements)
surveyed regarding their views about the key
“Given what you know about GTT, how would
elements of GTT and goals of communication,
you introduce it to a patient? Identify three (3)
which were consistent with the ideal of shared
essential things the patient needs to know.”
decision making (SDM). Study findings will be
used to design patient education and physician • Frequencies of multiple-choice responses were
tabulated.
training programs to promote SDM in GTT.
• Analysis of open-ended items was conducted
using qualitative methods.
Background
• Software-assisted coding with MAXQDA™
• Genomic tumor testing (GTT) is a new
technology and a cornerstone of the
“precision medicine” movement in cancer
care.
• GTT uses next-generation genome
sequencing technology to identify somatic
variants in tumor cells.
• By identifying somatic variants that predict
responses to cancer therapies, GTT can help
tailor therapy to individual patients, making
them more effective.
• However, GTT also detects many variants of
uncertain significance, its clinical value is
currently unproven.
• When using GTT, physicians need to counsel
patients about both its value and its
limitations, but the ideal goals and elements
of physician-patient discussions have not
been clearly defined.
• The Jackson Laboratory’s Maine Cancer
Genomics Initiative (MCGI) is a 5-year statewide research project aimed at disseminating
and implementing GTT in community
oncology practices throughout the state of
Maine.

Research Question
What are providers’ perceptions of the key goals
and elements of physician-patient discussions
about GTT?

Key Content Elements of Discussions
“Given what you know about GTT, how would you introduce it to a patient?”

Key Elements of Physician-Patient Discussions

Nature of GTT
(n=201)

GTT Background
Information
(n=48)

Uncertainty about
GTT
(n=59)

Potential
Outcomes of GTT
(n=25)

Uncertainty about
Therapeutic Options
(n=26)

Patient
Expectations
(n=24)

Uncertainty from
Incomplete
Evidence
(n=10)

Results
Participants
Oncology physicians

n
17

Registered nurses
Genetic counselors

14
5

Pathologists
Other (e.g. practice administrators, genetic
counselors, other physician specialists)
Total

5
35

Logistics of
Testing
(n=43)

Genetics
&
Genomics
(n=21)

Discovery of
Germline
Variants
(n=11)

Potential
Harms
(n=7)

76

Key Goals of Discussions

Illustrative Quotations from Open-ended Responses

“What do you think are the three (3) most important
goals when introducing genomic tumor testing?”
Goal Options
Inform patients about benefits and
limitations of genomic tumor testing
Manage patients expectations about
genomic tumor testing
Facilitate decision making
Understand patient preferences for
genomic tumor testing
Maintain patient hope
Encourage patients to undergo genomic
tumor testing
Share your personal viewpoints on
genomic tumor testing

Therapeutic
Implications
(n=43)

n
66
56
54
30
9
3
1

Discuss
nature of
GTT

Convey
uncertainty
about GTT

v “Every cancer is unique / This is a way to utilize precision medicine and offer a
more personalized treatment based on cancer genomics and identifying specific
genes and mutations associated with patient’s individual cancer”
v “Testing the cancer genome and not germline/ Looking for an unusual and novel
alteration in the genome that may give us insight into additional ways to treat
your cancer”

v “The chance of finding a practical – treatment is small but if found could
lead to major benefit”

v “Emerging technology; some meaning well understood, some not”
v “There may be no information that helps at this time but potential for future
treatment”
Maintain
v “The results may help identify one, none, or several mutations in your tumor /
we hope the results will help guide future treatment options, however we don’t
expectations
always find mutations that we can take action on- or change the treatment”
about GTT

Conclusions

• Cancer care providers identify several
different goals for physician-patient
discussions about GTT
• The most commonly prioritized goals
relate to informed and shared
decision making, and managing
patient expectations.
• Providers identify a variety of different
content elements for physician-patient
discussions about GTT: nature of GTT,
uncertainties about its value for treatment
decisions, and patient expectations
• Key elements regarding the nature of
GTT focus mainly on the meaning
and rationale for GTT, rather than its
potential harms or disadvantages.
• Key elements regarding uncertainty
in GTT focus mainly on therapeutic
options and incomplete evidence.
• Future research directions:
• Replicate and assess the
generalizability of the findings in a
larger, more diverse sample.
• Assess patients’ perceptions of the
goals and ideal content of physicianpatient discussions of GTT.
• Develop and test patient education
and decision support interventions to
facilitate informed and shared
decision making about GTT.
• Develop and test interventions to
train physicians in facilitating shared
decision making and managing
patient expectations about GTT.
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Flow Cytometric Analysis of Circulating
Microparticles After Cardiac Arrest
RESULTS

Flow cytometric analysis: was performed using a MACSQuant®
Analyzer 10 (Miltenyi Biotec, Inc.) and the data were analyzed
with WinList 5.0 software. Trucount and sigma microbeads were
used to set gates and calculate the number of circulating
microparticles.
Data: Data were analyzed with GraphPad Prism 7.0 (GraphPad
Software Inc., San Diego, CA). Comparisons between two
groups were performed using two-tailed unpaired t tests.
Comparisons between several treatment groups were
performed using one-way ANOVA followed by Multiple
comparison tests. A P value < .05 was considered significant.
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Figure 2. The number of circulating microparticles in СA subjects at 6 hours is
significantly higher compared at 24 hours and 72 hours after ROSC. Control (CABG, n =
36) patients do not have a significant difference in the number of circulating microparticles
compared to any of the CA subjects (n = 44). Statistical significance was calculated using oneway ANOVA, p values from Dunn’s multiple comparisons test are indicated.
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Figure 3. There is no difference in number of microparticles between CA and control subjects.
Circulating microparticles were measured in platelet-free plasma of CABG subjects (control, n= 36) , survivors
(n=19) and non-survivors (n=22) after CA at different time points after ROSC. Statistical significance was
calculated using one-way ANOVA, p values from Dunn’s multiple comparisons test are indicated.
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Figure 1. Flow cytometric gating strategy to calculate the number of circulating
microparticles in platelet-free plasma. Fluorescencein isothiocyanate-labeled (FITC-labeled)
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percentage of all events that occur in the gate. This diagram shows that all of the microbeads
are removed by the 0.1 micrometer filter.
150

M ic r o p a r tic le s , x 1 0 / l

SSC-H
10 2

10 1

1

100.0%

SSC-H

SSC-H
10 2
10 1
10

FITC-A

SSC-H

SSC-H

SSC-H
10 2

0.0%

n tr

48 Hours Post ROSC
p = 0.074
p > 0.999
p = 0.199

All events
10 3

10 3

10 3

GATE: Microbeads-FITC

100

0

Co

0.0%

M ic r o p a r tic le s , x 1 0 / l

2

6

10
FSC-H

5

p = 0.734
p = 0.462
p > 0.999

150

M ic r o p a r tic le s , x 1 0 / l

1

6

6

10 1
10

FSC-H

10

6

5

50

200

M ic r o p a r tic le s , x 1 0 / l

10

100

6

4

5

150

M ic r o p a r tic le s , x 1 0 / l

10

10

M ic r o p a r tic le s , x 1 0 / l

10 3
FITC-A

50

p > 0.999
p > 0.999
p > 0.999

200

M ic r o p a r tic le s , x 1 0 / l

2

0.2 µm

100

6

10

0.5 µm

150

M ic r o p a r tic le s , x 1 0 / l

1

0.2 µm

SSC-H

10

1 µm

SSC-H

10 1

0.5 µm

M ic r o p a r tic le s , x 1 0 / l

10 3

1 µm

p > 0.999
p = 0.08
p = 0.027

200

100.0%

SSC-H
10 2

10 3

All events

99.5%

SSC-H
10 2

10 3

0.2 µm

SSC-H

GATE: Microbeads-FITC

Filter pore
size: 0.1 µm

METHODS

Cerebral Performance Category (CPC): CPC is a neurological
test based on a scale of 1 through 5. 1 being the best and 5
being the worst.
1 - return to normal cerebral function and normal living
2 - cerebral disability but sufficient function for independent
activities of daily living
3 - severe disability, limited cognition, inability to carry out
independent existence
4 – coma
5 - brain death

0.5 µm

FITC-A

Since CA is associated with global ischemia/reperfusion-induced
cellular stress and apoptosis, we hypothesized that the number
of circulating microparticles should increase in CA patients.

Plasma Samples: Venous blood (10 ml) was collected from
cardiac arrest and control CABG subjects using BD Vacutainer
ACD tubes. Platelet-free plasma was prepared at room
temperature using two-step centrifugation, each at 2,000g for 20
minutes. After preparation plasma was stored at - 800C until
further analysis.

1 µm

10 1

(0.2, 0.5 and 1 µm)

SSC-H
10 2

PBS and
FITC-labeled Microbeads

Microparticles are tiny particles in our blood. The two major
ways microparticles are created: 1) cellular activation/stress and
2) cell apoptosis. In addition, immune complexes add to the pool
of circulating microparticles. Microparticles are known to cause
inflammation, coagulation, and effect vascular function.

Study participants: Research was performed in accordance with
study protocols approved by Maine Medical Center Institutional
Review Board, which is accredited by the Association for the
Accreditation of Human Research Protection Programs
(AAHRPP). Post-CA subjects age 18 years or older, admitted to
the ICU after a cardiopulmonary arrest and treated with
Targeted Temperature Management were enrolled after
informed consent of the medicolegal Power of Attorney.
Subjects underwent phlebotomy at 6, 12, 24, 48, 72 and 168
hours after Return of Spontaneous Circulation (ROSC). Control
subjects underwent Coronary Artery Bypass Graft (CABG)
surgery. Inclusion criteria included patients 18 years of age or
older scheduled for open heart surgery supported by
cardiopulmonary bypass (CPB) at Maine Medical Center.

Microbeads-FITC

0.9%

10 1

INTRODUCTION

Cardiac arrest (CA) is an electrical malfunction of the heart that
causes an irregular heartbeat (arrhythmia). Because of this
arrhythmia an insufficient amount of blood is pumped to the vital
organs. CA has a survival rate of only 10 percent and those who
survive suffer from post-cardiac arrest syndrome (PCAS). PCAS
is defined as a condition after resuscitation following a massive
ischemia-reperfusion injury to all organs most notably of but not
limited to the brain. PCAS is characterized by development of
systemic inflammatory response, which contributes to additional
brain tissue damage.

Nathan L. Pinnette1, Mary Weatherbee1, Joanne Dekay1, M.S., Sarah Peterson1, M.D., PhD, Angela Kosta1, B.S., Haifeng Yin1, PhD, Douglas
Sawyer1,2, M.D., PhD, Michael Robich1,2, M.D., David Seder2, MD, Sergey Ryzhov1, PhD
1Maine Medical Center Research Institute, Scarborough, ME
2Maine Medical Center, Portland, ME
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Figure 4. Good CPC scores have significantly higher numbers of circulating microparticles compared
to undesired CPC scores for CA subjects 48 hours after ROSC. Circulating microparticles were measured
in platelet-free plasma of good and poor CPC scores after CA at different time points after ROSC. Statistical
significance was calculated using t tests, p values from Mann-Whitney test are indicated.

CONCLUSIONS
The number of circulating microparticles is not different between CA and control (CABG) patients.
The number of circulating microparticles is characterized by high variability on day two after cardiac arrest with significantly increased
number of microparticles in CA patients with good CPC scores compared to CA patients with poor CPC scores.
Immunophenotypical analysis should be performed to determine if CA induces changes in origin of circulating microparticles.
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Sympathetic and sensory innervation of bone
modulates remodeling

Nick Banks; Audrie Langlais BS; Audrey Bergeron MS; Roni Kunst MS ; Adriana Lelis Carvalho (PhD), K. Motyl, (PhD)
Center for Molecular Medicine (CMM), Maine Medical Center Research Institute (MMCRI), Scarborough, ME, US.

Abstract
Research on the relationship of skeletal physiology and the nervous system has exploded in
the last 25 years2. Studies of β-adrenergic ligands and bone density have well established an
inverse relationship between sympathetic nervous output and bone metabolism (Figure 1)5.
Recently, the role of sensory nerves have also been considered to the story (Figure 2) . The
precise mechanisms of neuro-osteogenic crosstalk remain obscured. A better understanding
innervation with respect to bone remodeling will inform treatment of bone pathologies and
disease4. We use immunohistochemical staining techniques to elucidate the phenotypes,
distribution and organization of nerve fibers in bone. Semiconductor nanocrystals (quantum
dots) have more desirable optical qualities than organic dyes and fluorophores6, and will be
used to overcome the inherent difficulty in confocal imaging of bone.

Methods and Materials
•
•
•
•

Discussion

Fixed, frozen tissue sections of long bones and L5 vertebrae from transgenic mice
expressing gfp driven by sequence under trpm8 promoter.
IHC performed to visualize neural markers and trpm8 with fluorescent markers.
Quantum dots (Figure 4) conjugated to secondary antibodies (Figure 3) in lieu of organic
fluorophores; for signal amplification to compensate for high auto fluorescence and as proof
of principle for future studies.
Images (Figures 6,7) from confocal microscope analyzed with Autoquant and Imaris
software.

Unfortunately, we have not yet optimized technique enough to isolate meaningful signal from
background, although positive staining has generally been in the reasonable location but lacks any
“nerve like” morphological characteristics. Must titrate to detergent concentration, antibody
type/dilution/incubation times to optimize staining. Rigorous negative controls and positive controls
(with dorsal root ganglia) will be required to confirm specificity of assay results. Further investigation of
trpm8 localization in bone needed to reveal any potential role in mediating bone homeostasis.

Future Directions
•

Figure 3. Indirect Immunofluorescence with Quantum Dot

•
•

Figure 8. 3d Reconstruction (Autoquant)
of Figure 7 with potential neurons
traced with Imaris “filament” algorithm

Antigen of interest

Introduction

Multiplex imaging (Figure 9) of multiple neural markers and receptors (TH, CGRP, TRPM8, ) to show
colocalization, giving clues to communication mechanisms.
Quantitative comparison of neural organization and density between long bones and vertebrae.
Study changes in neural density from neuropathy in mouse BTBR Ob/Ob diabetes model.

100 μm

Figure 4.

Bone remodeling is a continuous, ubiquitous process. Sympathetic nervous output shifts
this equilibrium towards increased resorption and decreased bone formation. The myriad of
factors by which the nervous system interacts with the skeleton (hormones, peptides,
neurotransmitters [serotonin], etc.) comprise a somewhat “black box” type system. There is
observable input and output, but incomplete understanding of the internal workings . The use of
immunofluorescent neural markers seems promising in shedding light on this system. However,
immunohistochemistry (IHC) and confocal imaging of bone present difficulties. The requisite
fixation time and decalcification reduces antigenicity. This diminishes signal strength, which in
addition to the high auto fluorescence and low neuron density of bone has lead to few labs
reliably able to perform these techniques routinely1.
An efficient, reproducible technique for visualizing and quantifying the differential
innervation of bones will be quintessential in understanding the complex network between bone
and brain3.

Figure 9. Design for single UV
excitation multiplex assay for
variety of neurochemical
phenotypes

Dapi/Trpm8

Figure 5. Flow chart of standard skeletal
preparation with changes in orange

Results
50 μm

Dapi

Figure 1. Sympathetic control of bone response4.

Figure 2. Afferent sensory nerves relay local
mechanical conditions to the brain

Figure 6. Strong evidence supporting sensory
innervation along periosteum of femur. Tropomyosin
Receptor Kinase A (Trka) is a NGF receptor and
localizes sensory nerve fibers. Confocal image with
20x objective, 405 nm excitation .

50 μm

Dapi/Trpm8
Figure 7. Inconclusive staining for sympathetic
innervation in growth plate of Tibia/Fibula. Tyrosine
hydroxylase (TH) is an enzyme involved in the
production of catecholamines and localizes
sympathetic nerve fibers . Maximum intensity
projection of confocal 10 μm z-stack, 20x objective.

Β3 Tubulin
(Pan neuronal marker)
TRPM8
(Cold receptor)
CGRP
(++Peptide Sensory Neurons)
Tyrosine Hydroxylase
(Sympathetic Neurons)
TrkA
(Sensory Neurons)
Acknowlegdements: This research is supported by NIH/NIAMS KO1AR067858 to KJM;
NIH/NIGMS P20GMS, P20GM12301 to KJM; NIH/NIGMS P30GM106391, P30GM103392,
P20GM121301 U54GM115516 to Maine Medical Center.
Contact: Katherine J. Motyl, 81 Research Dr. Scarbourough, ME 04074, www.mmcri.org;
motylk@mmc.org

Contact

References

[Nicholas Banks]
[MMCRI]
[Nicholas.banks@maine.edu]
[6145062825]

1. Chartier, S., Thompson, M., Longo, G., Fealk, M., Majuta, L. and Mantyh, P. (2014). Exuberant sprouting of sensory and sympathetic nerve fibers in nonhealed bone fractures and the
generation and maintenance of chronic skeletal pain. Pain, 155(11), pp.2323-2336.
2. Dimitri, P. and Rosen, C. (2016). The Central Nervous System and Bone Metabolism: An Evolving Story. Calcified Tissue International, 100(5), pp.476-485.
3. Kusumbe, A., Ramasamy, S., Starsichova, A. and Adams, R. (2015). Sample preparation for high-resolution 3D confocal imaging of mouse skeletal tissue. Nature Protocols, 10(12),
pp.1904-1914.
4. Motyl, K. and Barbe, M. (2018). Bone and the Brain (Chapter 18).
5. Motyl, K. and Rosen, C. (2012). The Skeleton and the Sympathetic Nervous System: It's about Time!. The Journal of Clinical Endocrinology & Metabolism, 97(11), pp.3908-3911.
6. Rosenthal, S., Chang, J., Kovtun, O., McBride, J. and Tomlinson, I. (2011). Biocompatible Quantum Dots for Biological Applications. Chemistry & Biology, 18(1), pp.10-24.

Published by MaineHealth Knowledge Connection, 2019

19

Journal of Maine Medical Center, Vol. 1 [2019], Iss. 1, Art. 16

Differential Gene Expression in Adipose Tissue
of M. musculus Fed a High Fat Diet
Samantha White, Larisa Ryzhova Ph.D., Josh Boucher Ph.D., Cal Vary Ph.D., and Lucy Liaw Ph.D.
Proteins enriched in M. musculus adipose tissues on HFD

Fig. 1. Differential phenotype of
perivascular adipose tissue in healthy
individuals vs. cardiovascular disease.

Perivascular adipose tissue (PVAT) surrounds the systemic
vasculature of the body where it acts as mechanical support and
secretes cytokines that affect the profile of the underlying vessel.
The direct proximity of PVAT to the adventitia of blood vessels
and its secretion of vasoactive factors that regulate vascular tone
make it especially relevant to the study of cardiovascular disease.
In healthy individuals, PVAT produces anti-inflammatory and
anticontractile cytokines that promote vascular health. In
cardiovascular disease and obesity, dysfunctional PVAT reduces
vascularization and increases inflammatory response and
vasoconstriction. Currently, there are no known molecular
markers unique to PVAT, which limits investigation into possible
treatments to encourage a healthy PVAT profile. The discovery of
PVAT specific markers would allow for the development of novel
tools to study this depot, and could lead to clinically relevant
interventions to improve vascular function.

Gene candidate selection

High Fat Diet

Regular Diet
gWAT
BAT

Control Diet
Protein Signatures

PVAT

High Fat Diet
Protein Signatures

Fig. 2. Proteomic assay performed on tissues
collected from M. musculus fed a HFD or CD
for 12 weeks.

Proteomic data highlighted differential expression
of proteins in perivascular adipose tissue (PVAT) of
mice fed a high fat diet (HFD) versus those fed a
control diet (CD). Twelve candidate genes with
significantly different protein levels were identified
as potential protein markers unique to perivascular
adipose tissue.
Candidates were divided into two categories: those
proteins upregulated in gonadal white adipose
tissue (gWAT), brown adipose tissue (BAT), and
PVAT in mice fed a high fat diet; and proteins
upregulated in BAT and PVAT and downregulated in
gWAT of mice fed a high fat diet. Transcriptome
verification via qRT-PCR of the first category was
performed.

Methodology
• Mapping of genomic DNA and mRNA and primer design for candidate
genes
• Stringent validation of primers in multiple tissues
• Mechanical homogenization of experimental tissues
• RNA isolation: Tissue lysis and affinity chromatography purification
• qRT-PCR amplification and analysis of relative transcript abundance

Tissue
RNA
qRT-PCR
Analysis

https://knowledgeconnection.mainehealth.org/jmmc/vol1/iss1/16
DOI: 10.46804/2641-2225.1017

Gene
S27A2
HMCS2
PLIN2
ANXA1
HSDL2
TAGL2

Name
Very long-chain acyl-CoA synthetase
Hydroxymethylglutaryl-CoA synthase
Perilipin-2
Annexin A1
Hydroxysteroid dehydrogenase-like protein 2
Transgelin-2

gWAT CD
1,041
6,771
16,034
1,311,051
142,657
773,866

gWAT HFD
BAT CD
BAT HFD
PVAT CD
PVAT HFD
6,294
19,618
33,436
2,436
16,485
50,776
2,399
6,749
2,115
11,594
219,927
19,137
33,800
14,437
41,056
2,012,223
84,678
138,520
49,419
132,267
156,959
317,538
475,215
136,610
309,144
1,083,330
198,420
293,259
123,726
196,127

Table 1. Candidate proteins displaying differential abundance from protein mass spectrometry of adipose tissues. Tissues were collected from mice
fed a high fat diet vs. control diet for twelve weeks.

Transcript abundance of candidate genes in BAT, IWAT, gWAT
250%
RNA % Fold Change HFD vs. CD

Perivascular adipose tissue and vascular health

200%
150%
100%

BAT
IWAT
gWAT

50%
0%
-50%
-100%
-150%

Plin2

Slc27a

Hmgcs2

Anxa1

Hsdl2

Tagl2

Fig 3. Differential RNA abundance in adipose depots on HFD. qRT-PCR results show differential RNA abundance in adipose depots
on HFD. Y-axis shows relative percent difference of HFD vs. CD as calculated using 2-∆∆Ct. Ppia (Cyclophilin A) was used as the
reference gene. qRT-PCR reactions contained 10ng of cDNA and 300nM primer concentration. Cycle: 95˚C, 3 min; 95˚C 15 seconds,
60˚C 30 seconds x 40 cycles. n=2.

Conclusion and future directions

The transcriptome did not directly corroborate the proteomic data, with the exception of Anxa1 and Tagl2. Moving forward, this
experiment will be extended to include PVAT from CD and HFD mice, and the data from all adipose depots will be validated at the
protein level via western blot. Candidate genes from the second category identified in the proteomic assay—proteins with higher
expression in PVAT and BAT but no change or a decrease in gWAT—will be evaluated along the same course as outlined here.
Genes determined to have differential expression in PVAT at the protein and transcript level, with be further investigated as potential
PVAT markers.
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Pediatric Interfacility Transfers – Association of Pre-transfer Vital Signs
with Length of Stay at a Tertiary Care Center
Sarah Bunting BA, Leah Mallory MD, Logan Murray MD
Maine Medical Center, Department of Pediatrics, Portland Maine

Background
• Interfacility transfers are common in rural states where few hospitals
admit children. Pediatric hospitalizations admitted via transfer cost
$19.5 billion in 2012.1
• As many as 25% of transferred pediatric patients are discharged
within 12 hours of arrival and do not have any further work-up.2
• Understanding what pre-transfer factors are associated with shorter
LOS may help avoid unnecessary transfers.

Objectives
1.) Determine whether an association exists between abnormality of
pre-transfer vital signs and LOS.
2.) Identify pre-transfer vital signs associated with morbidity, such as
unexpected transfer within 24 hours from the inpatient units (IPUs) to
the PICU.

Materials and Methods
• All pediatric direct admissions from referring hospitals and urgent
care centers to the Maine Medical Center IPUs and PICU, as well as
all transfers to the ED for evaluation by the pediatric hospitalist
service during the months of August 2016-January 2017 were
enrolled.

Transfer Patient Characteristics
Variable

Median [range], or n (%)

n

236

Age (months)

67.5 [0-225]

Male sex

122 (51.7)

Medical complexity:
Non-chronic
Non-complex chronic
Complex chronic

118 (50.0)
80 (33.9)
38 (16.1)

Admission type:
Direct to IPUs
Direct to PICU
Not direct

78 (33.1)
51 (21.6)
107 (45.3)

Hospitalist Service Involved

185 (78.4)

LOS (hours)

42.5 [2.6-1392]

Early Discharge/Unexpected Transfer:
D/C from MMC ED
Transfer from IPUs to PICU in 24h
Transfer to other hospital in 24h

13 (5.5)
10 (4.2)
1 (0.4)

Pre-transfer Vital Signs and Median LOS

• The patient’s electronic medical record and/or HealthInfoNet data
were manually reviewed. Data were entered into a secure database
(REDCap™).

p= 0.0171

• Medical Complexity was assigned using a standardized method.3

• It supports no significant correlation between abnormal HR,
temperature, and spO2 with LOS.
• These results may better help both referring and accepting providers
predict the course of patient care after transfer.

• Further research is necessary to increase the generalizability of this
study, with the addition of other hospitals.

• Statistical analyses were performed using SPSSTM statistical software,
version 25 (IBM SPSS Inc, Armonk, NY).

• Create a guideline where accepting pediatric providers obtain all five vital
signs before accepting the patient. This could allow for the study of
another objective measure of decompensation such as Bedside Pediatric
Early Warning System (BPEWS) with LOS.
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Conclusions
• This study demonstrates a significant association between both
abnormal pre-transfer RR and BP with longer LOS in pediatric patients
at a tertiary care facility.

Next Steps

• Vital signs were determined to be abnormal or normal using the
Pediatric Advanced Life Support (PALS) algorithm.4

1.) Rosenthal JL, Hilton JF, Teufel RJ, 2nd, Romano PS, Kaiser SV, Okumura MJ. Profiling
Interfacility Transfers for Hospitalized Pediatric Patients. Hosp Pediatr. 2016;6(6):345-353.
2.) Gattu RK, De Fee AS, Lichenstein R, Teshome G. Consideration of Cost of Care in Pediatric
Emergency Transfer-An Opportunity for Improvement. Pediatr Emerg Care. 2017;33(5):334-338.
3.) Simon TD, Cawthon ML, Stanford S, et al. Pediatric medical complexity algorithm: a new
method to stratify children by medical complexity. Pediatrics. 2014;133(6):e1647-1654.
4). Pediatric advanced life support: Provider Manual. Dallas, TX: American Heart Association,
American Academy of Pediatrics; 2016.

p= 0.0351

Results
• Many patients were discharged quickly after transfer; 5.9% in <6 hours;
11.9% in <12 hours; and 30.9% in <24 hours.
• Most vital signs were reliably obtained (HR for 93.6% of patients; RR,
90.7%; temperature, 87.3%; spO2, 92.4%). BP was an exception at
47.9%.
• Patients with abnormal RRs before transfer have significantly longer
LOS than patients with normal RRs (61 v. 38 hours, p= 0.017). The
same finding was apparent for BP (57 v. 31 hours, p= 0.035).
• Abnormal HR, temperature, and spO2 alone did not correlate with
LOS.
• When controlling for temperature, there was no significant difference in
LOS for patients with pre-transfer abnormal HRs.
• Younger patients were less likely to have a recorded BP (p=<0.001),
with a 10.75 year gap in median ages.
• Apparent trend toward abnormal RR being associated with unexpected
transfer to PICU in 24 hours. Six out of 8 unexpected transfers had
abnormal RRs.
• Additionally, median LOS increased with medical complexity (p= 0.028).
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3T3-L1 model of adipogenesis and effects of methionine restriction
Sharon Jordan, Emily Cooper, Lucy Liaw PhD
Maine Medical Center Research Institute, Scarborough, Maine.
Sharonajordan@smccme.edu

Results

Abstract

Culture and Differentiation 3T3-L1 model of adipogenesis
The 3T3-L1 cell line was used to study adipogenesis in vitro. The 3T3-L1 line has a fibroblast-like
morphology when grown under standard culture conditions. (see fig.1) Media consists DMEM/F12 with
10% FBS. For differentiation, 3T3-L1 cells were grown to 75-80% confluence and switched to
adipogenesis induction medium. After 72 hours induction cells were switched to maintenance medium.
The maintenance medium was changed every three days, leaving 25% medium in the plate and adding
75% fresh maintenance medium. Cells are maintained in maintenance medium for 8 to 10 before
collection?

Methionine Concentration Variations in Media
To make medium with varying concentrations of methionine, DMEM/F12 and DMEM high glucose with
no methionine was ordered (Gibco). Dialyzed FBS was used to ensure no added methionine was present.
Induction and maintenance medium was made using methionine the methionine free components.
Methionine free medium is mixed with standard medium to obtain desired concentrations.

Analysis of Adipocyte Differentiation
To determine the level of lipid accumulation oil red o (ORO) staining was used. The ORO stock solution
is 0.35g ORO per 100ml 100% isopropanol. The working solution is 3 parts ORO stock 2 parts diH2O
(0.05µg/ml). Cells were fixed in 10% neutral buffered formalin. Formalin was added slowly to the side of
the well and aspirated off after one hour. Cells were rinsed with diH2O. After aspirating off the diH2O,
60% isopropanol was added to the well and the plate rotated to cover the cells.. The isopropanol was
https://knowledgeconnection.mainehealth.org/jmmc/vol1/iss1/16
aspirated, and the ORO working solution added and incubated for 10 minutes on a rocking platform. The
ORO solution was removed, and cells rinsed with diH2O twice followed by 3x10 minute diH2O washes
DOI: 10.46804/2641-2225.1017
on a rocking platform. Images were taken of the cells to document the ORO staining. The ORO stain was
eluted with 100% isopropanol, and the absorbance of the solution was measured at 490 nm.

a

b

Figure 1. Adipogenic differentiation of 3T3-L1 cells
a) 3T3-L1 cells before differentiation. b) 3T3-L1 cells after successful differentiation and lipid stained with oil red O.

Effects of methionine modification on adipocyte cell number and
differentiation

a

b
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Materials and Methods

3T3-L1 model of adipocyte differentiation

Cristal violet, ug/ul

Healthy adipose tissue has an important role as an endocrine organ that affects whole body health.
One example is the secretion of adiponectin, a hormone that aids in regulating glucose levels and
breakdown of fatty acid. There are several types of adipose tissue. Perivascular adipose tissue
(PVAT) surrounds most of the large blood vessels including the aorta. PVAT has thermogenic and
vaso-protective properties. In obesity PVAT exhibits structural and functional changes. Unhealthy
adipose tissue can become inflamed and inhibit the beneficial adipokines. Methionine reduction
has shown to increase health span in mouse models. The methionine restricted mice continued to
maintain healthy weight and improved glucose metabolism. To understand how methionine
restriction alters adipose tissues, we initially used the 3T3-L1 cell line. 3T3-L1 is a fibroblastic line
that can be differentiated into adipocytes and will be a useful model for altering methionine during
adipogenesis in vitro. We used an adipogenic cocktail to induce these cells along the path to mature
adipocytes. Oil Red O staining was used to view lipid accumulation and we performed initial
studies with different concentrations of methionine in the medium. Our next aim is to test if the Disomer of methionine is metabolized differently than the L-isomer. This is important to develop an
accurate optimal methionine concentration. Having a cell model will be beneficial for future study
into activities of methionine restriction in adipocytes. In addition, it will set the stage for continued
studies with primary cells derived from PVAT.

300
250
200
L-met

150

DL-met

100
50
0
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0.018 mM
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Figure 2. Effects of methionine modification on adipocyte cell number and differentiation
a.) Absorbance of crystal violet dye was measured to estimate the amount of cells that survived under each methionine
condition. b.) Oil red O was used to stain the lipid. Amount of Accumulated Oil Rd O was normalized to amount of CV in
corresponding cells.

Conclusions and Discussion
We confirmed that 3T3-L1 cells have the capacity to differentiate into
adipocytes based on oil red O staining of neutral lipids in the differentiated
cells. Using these cells as a model to test the effects of methionine restriction
on the adipogenic capacity of the cells, we found that cells containing a
racemic mixture of 0.0184mM methionine (D and L isomers) had enhanced
survival and reduced lipid accumulation as compared to other tested
concentrations of methionine. These results suggest that methionine is
content is an important regulator of adipogenesis. This data shows that in the
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Characterizing the pluripotency of human thoracic
perivascular adipose tissue progenitor cells
S. Spencer Scott, Joshua Boucher, Xuehui Yang, Lucy Liaw

This work was possible thanks to the generosity of Beth DeTine and the Paul Gray Scholarship.

Adipogenic

Abstract

While burgeoning research on perivascular adipose tissue begins to illuminate the complex relationship between these unique
fat deposits and the blood vessels to which they are localized, broad cellular and molecular characterizations of PVAT are still
sparse. Furthermore, work with PVAT specimens collected from human donors remains limited in this exciting area of vascular
research. At the Liaw lab, thanks to a collaboration with surgery at Maine Medical Center, human thoracic PVAT samples have
been collected incidentally during cardiac surgical procedures and primary human PVAT cells have been explanted from the
collected tissue. This project attempts to explore the nature of these explanted cells, presumed to be the progenitor cells that
reside among PVAT and replenish the tissue in periods of regeneration or growth. A major question regarding these cells is the
extent of their pluripotency. To probe this question, this project attempted to induce the PVAT primary cells toward an
adipogenic, osteogenic, and chondrogenic lineage in three concurrent induction assays. The cells were cultured for 14 days in
their respective induction media and then fixed in formalin. Subsequently, the cells were stained using Oil Red O to assess the
success of adipogenic induction, Alizarin Red for osteogenic induction, and Masson’s trichrome for chondrogenic induction. This
preliminary work seems to suggest that these human primary PVAT cells are capable of adipogenic and chondrogenic
differentiation, but incapable of induction toward an osteogenic lineage.

Background

20X

1b

PVAT
1c

20X

Non-induced

PVAT
Perivascular adipose tissue, or PVAT, is a specialized form of
fat tissue that encompasses major vasculature in the body.
While this tissue was once thought to be primarily structural in
nature, PVAT is now understood to play a significant role in
regulating vascular health. In metabolically healthy
individuals, PVAT both promotes vasodilation and inhibits
inflammation. In metabolically unhealthy individuals, as in
conditions of obesity, PVAT expands through a process called
hypertrophy and loses its protective functions, exacerbating the
risk of cardiovascular disease. Since 2016, the Liaw lab at the
MMCRI’s Center for Molecular Medicine has made the study of
perivascular adipose tissue a primary focus of its work.
Through a collaboration with cardiac surgery at Maine Medical Center, the
Liaw lab has been able to receive human PVAT specimens collected
incidentally during coronary artery bypass graft (CABG) procedures. To
accommodate grafting the new vasculature to the aorta, the local PVAT tissue
must be cleared away. These samples are then provided to MMCRI for
multiple avenues of study, including explanation of primary cells.

40X

1a

Fig. 1. Following 14 days of induction, the explanted
human thoracic PVAT cells displayed a robust ability to
differentiate toward an adipogenic lineage as assessed by
the accumulation of neutral lipids, stained here with Oil
Red O. In image 1c, the non-induced condition is shown at
14 days with virtually no apparent neutral lipid
accumulation.

Osteogenic
20X

20X

2a

2b

PVAT

Bone Marrow MSC

Fig. 2. In the osteogenic induction assay human bone marrow mesenchymal stem cells were cultured alongside human thoracic
PVAT cells, both in osteogenic differentiation medium. At the end of 14 days of induction, Alizarin Red was used to stain for free
calcium and calcium compounds, evidence of mineralization and osteogenic induction. Staining of the bone marrow MSCs showed
a markedly larger amount of mineralization than the PVAT cells, in which the staining was sparse. This suggests that the human
thoracic PVAT cells were not able to differentiate toward an osteogenic lineage by the 14 day time point, unlike the MSCs.

Chondrogenic
10X

Human PVAT-APC differentiate to adipocytes in vitro a) Oil red O (ORO) staining of lipids in non-induced (top) and
induced (bottom) at day 7. b) Immunoblot for the indicated proteins of non-induced and induced PVAT-APC for 7 and 14
days.

The Liaw lab’s Joshua Boucher, PhD, has been able to explant progenitor cells from these human PVAT samples and
successfully induce them to differentiate toward an adipogenic lineage. The success of differentiation was assessed by
staining for neutral lipid accumulation with Oil Red O as well as probing for expression of genes specific to mature
adipocytes, such as PPARγ and PLIN1 or perilipin 1. However, a major question still remains: How committed are these
progenitor cells yielded by explantation of human thoracic PVAT to an adipogenic lineage? This project seeks to begin to
illuminate the pluripotency of these primary cells by examining their ability to differentiate toward other cell lineages,
specifically osteogenic and chondrogenic.

Published by MaineHealth Knowledge Connection, 2019
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Fig. 3. In the chondrogenic induction assay, shown in these images, human thoracic PVAT cells
were cultured using a “micromass” technique which allows for the growth of a pellet of roughly
107 cells in the center of a culture dish. These cells were cultured in chondrogenic differentiation
media for 14 days and then the cell pellet was embedded in paraffin and stained using Masson’s
trichrome, of which the blue stains for collagen. In multiple pellets of human thoracic PVAT cells,
the structure was positive for collagen, suggesting successful induction toward a chondrogenic
lineage.
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Neoadjuvant Therapy versus Upfront Surgery for Resectable Pancreatic Cancer
using the NCDB database: A Decision Analysis
William Olsen BA, Roberto Vidri MD, David Clark MD, Timothy Fitzgerald MD
Maine Medical Center, Department of Surgery, Portland Maine

Background

Kaplan-Meier Survival Curves

• Pancreatic adenocarcinoma (PAC) is the third leading cause of cancerrelated death in the United States and an estimated 44,330 people will die
from PAC in 20181.
• The only curative treatment at this time is resection, yet only 10-20% of
patients are considered clinically resectable at the time of presentation2.
• Currently there are no prospective clinical trials that have shown benefit of
neoadjuvant therapy (chemotherapy first) compared to upfront surgery in
resectable PAC patients, and there are only retrospective single-institution
studies3.
• Studies have have shown that receiving chemotherapy at some point is
advantageous compared to just surgery, but the sequence is debated4.

Decision Tree

P value:
0.1958

Objectives

• Compare the overall survival rates of patients with stage I and II
resectable pancreatic adenocarcinoma who receive neoadjuvant
chemotherapy and surgery versus patients who receive upfront surgery
and adjuvant chemotherapy.
• Use a decision analysis to compare neoadjuvant therapy and upfront
surgery, including rates of dropout from each group.
• Identify therapeutic and pathologic characteristics of neoadjuvant and
upfront surgery patients associated with improved survival.

P value:
<0.0001

Materials and Methods

• Retrospective cohort study utilizing the NCDB database from 2004-2015
comparing patients who received neoadjuvant therapy and surgery versus
patients who received upfront surgery and adjuvant therapy.
• 32,498 patients were selected by the following characteristics:
• Invasive behavior of the tumor
• Histology of Carcinoma NOS (8010), Adenocarcinoma (8140), and
Ductal carcinoma (8500)
• TNM Stage I and II
• T1N0M0, T1N1M0, T1NXM0, T2N0M0, T2N1M0, T2NXM0

• Patients undergoing palliative care were excluded
• Patients who refused surgery were excluded
• Descriptive statistics were used analyze the data
References
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Conclusions

Variable

HR (95% CI)

P value

Age, 65-79

1.15 (1.09-1.21)

<0.0001

Age, 90-99

1.62 (1.58-1.77)

<0.0001

Male

1.05 (1.01-1.08)

0.004

White

1.02 (0.97-1.07)

0.439

Medicare

1.02 (0.96-1.08)

0.551

Private insurance

0.88 (0.83-0.93)

<0.0001

Academic center

0.79 (0.77-0.82)

<0.0001

Metropolitan area

0.92 (0.88-0.95)

<0.0001

Comorbidities

1.15 (1.11-1.18)

<0.0001

Poor tumor grade

1.26 (1.21-1.31)

<0.0001

Head/Neck Tumor

1.09 (1.06-1.14)

<0.0001

Start with Surgery

0.48 (0.46-0.49)

<0.0001

• Though chemotherapy before surgery has a slightly higher 5 year
survival rate when compared to the surgery first group, the dropout rate
is such that 72.1% of patients never make it to surgery, thus never
giving them a chance for a cure.
• Using the decision tree, there is a 13.1%, 5 year survival benefit to
receiving surgery first.
• Using Cox Regression analysis, patients were more likely to receive
surgery if they had private insurance, were at an academic center, and
lived in a metropolitan area.
• Patients were less likely to receive surgery first, if they were older than
65, male, had multiple comorbidities, had a poor tumor grade, had a
tumor of the pancreatic head or neck.
Next Steps

• Prospective, randomized controlled trials comparing neoadjuvant
therapy against an upfront surgical approach are needed to
better answer this question.
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INFLUENCE OF LYSOSOMAL ACID LIPASE ON OSTEOBLAST
DIFFERENTIATION AND FUNCTION
Talia Staiger¹, Elizabeth Rendina-Ruedy1, Ron C. Helderman1, Liv Palma1, and Clifford J. Rosen1
1Maine

Medical Center Research Institute, Scarborough, ME, 04074

METHODS

INTRODUCTION
● Lysosomal acid lipase (LAL) is an enzyme in the lysosome that breaks down
cholesteryl esters (CE) and triacylglycerides (TAGs).¹
● In humans, an LAL deficiency presents itself in two diseases:
○ Wolman Disease -, infants experience severe hepatosplenomegaly and
malabsorption and usually die before one year of age
○ Cholesteryl ester storage disease - later onset and milder phenotype, resulting in
CE storage in visceral tissues, hepatosplenomegaly, and hypercholesterolemia.¹
● LAL knockout (KO) mice have increased TAG
and CE storage in various tissues ², as well as
defective brown adipose tissue, leading to
hypothermia at room temperature.³

Bone Marrow Stromal (BMSC) Cell Culture

Lalistat Treatment

● C57BL/6 mice were sacrificed and their femurs, tibias, and iliac
crests were obtained. Their bone epiphyses were cut off to
remove the bone marrow through centrifugation with minimal
medium. The bone marrow pellets were resuspended,
distributed into flasks with 25 mL alpha MEM complete
medium, and incubated for 48 hours.
● The media and non-adherent cells were aspirated off and the
adherent cells (BMSC) were treated with 3 mL of trypsin for
three minutes before 20 mL alpha MEM complete medium was
added. The cells were counted and plated at a concentration ofBMSCs
5.0 x 10 ⁵ cells per well in three 12-well plates.

● After 48 hours, the alpha MEM complete medium was replaced with
osteogenic medium containing 50 µg/mL ascorbic acid and 5 mM βglycerolphosphate. The cells received this differentiation medium for
seven days.
● Throughout the differentiation, cells received various doses of Lalistat
at either 0µM (Control), 25µM, 50µM, or 100µM. This treatment also
lasted for seven days.
● At the end of the experiment (day 7) cells were stained for alkaline
phosphatase (ALP), an osteoblast marker.
ALP stain

Adapted from Hong Du, Journal of Lipid Research, 2001

● Recently, our lab has demonstrated

♂WT

Femur
Tibia
Iliac Crest

♂KO

LAL KO mice also have decreased
bone volume/ total volume (BV/TV)

Harvest bone marrow

Adherent
BMSCs

Isolate BMSCs from
total Bone Marrow

in the distal femur metaphysis.

Plate BMSCs

Osteoblast Differentiation
+/- Lalistat Treatment

RESULTS

Unpublished data.

SCHEMATIC DEPICTING LAL’S ROLE

Osteoblast Diff
Lalistat
(7 days)

FIGURE 1. ALKALINE PHOSPHATASE STAINING OF BMSCS AFTER 7 DAY LALISTAT TREATMENT
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a) This plate, stained at 7 days, shows increased amounts of
staining in the control group compared to the 100 µM group.

b) This plate, stained at 7 days, shows slightly increased
staining in the 100 µM group compared to control.

Free fatty acids

c) This plate, with cells grown during a different week
than the other plates, shows equal amounts of
staining across the wells, and more staining compared
to the first two plates at 7 days.

Free cholesterol

“Normal” LAL

LAL Deficiency

FIGURE 2. 10X IMAGES OF BMSCS FROM
FIGURE 1A ON DAY 5

HYPOTHESIS AND EXPECTED OUTCOMES
● We hypothesized that LAL supports osteoblast differentiation.
● It was expected that higher doses of Lalistat, an LAL inhibiting drug, would slow the
differentiation of osteoblasts and result in less alkaline phosphatase (ALP) staining.

CONCLUSIONS & SUMMARY
● ALP stains showed mixed results amongst the three plates, making the
results inconclusive even though the photographs showed less confluence
in the Lalistat-treated wells.
● This project taught me the techniques of bone marrow harvesting, cell
culture, osteoblast differentiation and ALP staining. Additionally, I was
exposed to genotyping/ PCR, Cre LoxP models, Seahorse XF96 technology,
and Confocal Microscopy.
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a) A well from the (0 uM) control
group of bone marrow stromal cells

b) A well from the 100 µM lalitstat
group of bone marrow stromal cells

(1) Du, H. (1998). Targeted disruption of the mouse lysosomal acid lipase gene: long term survival with massive cholesteryl
ester and triglyceride storage. Human Molecular Genetics, Vol. 7.
(2) Du, H. (2001). Lysosomal acid lipase deficient mice: depletion of white and brown fat, severe hepatosplenomegaly, and
shortened life span. Journal of Lipid Research, Vol. 42.
(3) Duta-Mare, M. (2018). Lysosomal acid lipase regulates fatty acid channeling in brown adipose tissue to maintain
thermogenesis. BBA - Molecular and Cell Biology of Lipids.
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Predicting Neurological Outcomes Using Pupillometry During Targeted Temperature Management After A Cardiac Arrest
Tyler R. Nussinow, Mary E. Sawyer, Dave Seder MD, Philip Stone DO, Richard R. Riker MD
Maine Medical Center, Neurocritical Care, Maine Medical Center Research Institute

Abstract

Results

A pupil’s reactivity to light during targeted temperature management (TTM) after
a cardiac arrest can help predict the neurological outcome of a patient. 1 This
was investigated by examining pupilometer data from patients admitted to Maine
Medical Center from August 2017 - July 2018. Neurological Pupil Index (NPi),
percent constriction and pupil size were compared to previously-established
thresholds1,2, while this is the first study, to our knowledge, to establish a
threshold for constriction velocity (via ROC curve). This data was conducted in
order to find trends consistent with good/poor neurological outcomes in patients
who suffer from cardiac arrests. A NeurOptics NPi-200 pupillometer was used by
nurses every few hours (no specific time requirement) both during and after TTM
in order to get objective pupil exams. Comparison of pupilometer data was done
by using patient’s worst scoring eye (in each respective category) between
Good or Poor outcomes and statistically analyzed by using Mann-Whitney, ChiSquared, and Fisher Exact tests. This study supports that NPi (=0 and/or <3),
percent constriction (<13%), and constriction velocity (<0.54mm/sec and <0.32
mm/sec) at different time periods (<6 hours after ROSC, <24 hours after ROSC,
or ever) are good predictors in neurological outcomes of patients after a cardiac
arrest.

N=1 N=15 N=24 N=8

N=5 N=11 N=32 N=9

ROC Curve CV at 6 Hours

N=6 N=11 N=35 N=7
ROC Curves NPi, CV, %C at 6 Hours

Introduction
*A

pupilometer is a device used to objectively measure pupil size and reactivity
to light – a pupil’s reactivity is thought to be directly correlated with brain
activity.1
*When a person has a cardiac arrest (CA), significant brain damage can result
due to lack of oxygen to the brain. Targeted temperature management
(TTM) has been demonstrated to reduce the amount of brain damage that
occurs in these patients.3
*The goal of this study was to examine data from the pupillometer (specifically
Neurological Pupil Index (NPi), percent constriction, constriction velocity, and
pupil size) and compare the values to suggested thresholds1,2 in order to
predict a person’s neurological outcome. We did this by looking at three time
intervals: 6 hours after return of spontaneous circulation (ROSC), 24 hours
after ROSC, and ever.
*Our hypothesis was that constriction velocity would be a more accurate
predictor of neurological outcome than NPi and size.

*Npi=0: 0 of 7 (0%) Good Outcome (n=7; p=0.0934)
*0<Npi<3: 2 of 12 (17%) Good Outcome (n=12;
p=0.3219)
*Percent Constriction Bilaterally <13%: 8 of 38 (17%)
Good Outcome (n=46; p=0.0003)
*Size >5mm: 5 of 16 (24%) Good Outcome (n=21;
p=0.8415)

Methods

Conclusions
https://neuroptics.com/npi-200-pupillometer/

CPC 1: Good cerebral performance: conscious, alert, able to
work, might have mild neurologic or psychologic deficit

CPC 5: Brain death: apnea, areflexia, EEG silence, etc.

GOOD

POOR

 Constriction velocity was an accurate predictor of poor neurological outcome.
 Constriction velocity <0.54mm/sec within 6 hours after ROSC associated with poor
outcome.
 Constriction velocity <0.32mm/sec 6+ hours after ROSC associated with poor
outcome.
 NPi value <3 confirmed as an accurate predictor of poor neurological outcome.1.
 Percent constriction <13% confirmed as an accurate predictor of poor neurological outcome.2
 Pupil size confirmed as not an accurate predictor of poor neurological outcome.

Next Steps
data from previous years in order to more accurately be able to demonstrate pupilometer data
 Compile
significance in predicting patient outcomes.
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Electrical Cardioversion of Emergency Department Patients with Atrial Fibrillation
Victoria Vargas; Tania Strout, PhD, RN, MS; Andrew Perron, MD
Emergency Medicine Department, Maine Medical Center, Portland, ME

ABSTRACT

This is a retrospective review of electrical cardioversion cases
performed in the emergency department over the last 6
years. By describing electrical cardioversion as a
management option in preference to other treatments for
atrial fibrillation, we will be able to identify factors that may
predict success for electrical cardioversion as a primary
management option. Most patients ultimately require
electrical cardioversion despite attempts at conversion with
medication. The average visit duration for cases of electrical
cardioversion was 206.67 minutes, whereas chemical
cardioversion requires hours of observation within the ED to
prove success in converting to NSR. Of these patients
requiring electrical cardioversion, 13.5% returned to the ED
for atrial fibrillation or related event within 30 days.

RESULTS

HYPOTHESIS

Emergency Department patients presenting with atrial
fibrillation will experience shorter, less frequent visits when
electrical cardioversion is utilized as a primary management
option for atrial fibrillation.

Figure 3: Average ED visit duration for those with attempted chemical
cardioversion verses those utilizing only electrical cardioversion

METHODS
Figure 1: Electrical cardioversion paddle placement on patient with atrial
fibrillation

n = 37

n = 612

Figure 4: Number of ED patients returning to the ED within 30 days for
atrial fibrillation or related event (n = 680)

INTRODUCTION
Atrial fibrillation (AF) is the most prevalent and frequently
encountered heart arrhythmia in adults, especially within the
emergency department (ED).
Figure 2: Sinus rhythm displayed on an EKG during 1) atrial fibrillation, 2)
during cardioversion shock, and 3) during return to normal sinus rhythm

http://www.alfalliance.org/contr
ol_rhythm.htm

With frequent ED encounters of atrial fibrillation, medical
costs, hospital visits and duration of procedures are high.
Studies have assessed rate control with chemical
cardioversion but unfortunately, successful conversion using
medications takes hours of monitoring each patient within
the ED with a lower success rate overall. Negative
assumptions about complications from electrical
cardioversion impede use at hospitals everywhere.

However, when used electrical cardioversion has the highest
overall success rate for patients presenting with atrial
fibrillation. Utilizing electrical cardioversion as a primary
treatment method for atrial fibrillation will lead to faster
patient turnarounds within the emergency department.

Published by MaineHealth Knowledge Connection, 2019

1

2

3

https://www.hrsonline.org/Patient-Resources/Treatment/Cardioversion

RESULTS
Table 1: Percentage of patients experiencing complications after
electrical cardioversion procedures within the emergency department
(n = 680)
Complication

Percentage of patients

HR < 50 bpm

3.4 %

Ventricular Tachycardia

1.8 %

Systolic BP < 90 mmHg

9.2 %

O2 saturation < 90%
Intubation/Bagged

4.0 %
0.7 %

CONCLUSIONS

• The average visit duration for patients requiring chemical
cardioversion was 331.8 minutes, verses the average
duration for those only undergoing electrical cardioversion
was 206.67 minutes.
• Only 13.5% of patients returned to the ED within 30 days
for atrial fibrillation or related event after undergoing
electrical cardioversion.
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Characterization of exosomes secreted from human thermogenic adipocytes
Zainab Miguel, Chad Doucette, Aaron Brown
Maine Medical Center Research Institute, Scarborough, Maine, Southern Maine Community College, South Portland, Maine

Abstract

Hypothesis

Accumulation of excess fat in white adipose tissue (WAT) is associated with an increase
in risk for type 2 diabetes (T2D). Unlike WAT, activation of brown adipose tissue (BAT)
burns calories by releasing energy stored in fats to generate heat. This process, termed
thermogenesis, correlates positively with a reduced risk for T2D. In addition to its fat
burning potential, secreted factors derived from activated BAT may enter the circulation
and reduce diabetic symptoms such as insulin resistance in other tissues. The
mechanisms by which these secreted factors act on distant tissues may in part be due to
their transport inside extracellular vesicles, known as exosomes. Exosomes carry a
diverse array of signaling molecules, including microRNAs, proteins and lipids that are
transported and released into recipient cells and tissues, potentially through direct
homing via specific cell surface receptors. The goal of this project was to determine if
brown adipocytes grown in cell culture secrete exosomes that contain microRNAs that
may harbor anti-diabetic properties. We found that miRNA-32, a microRNA previously
shown to activate brown adipocytes in a cell autonomous manner, can be packaged into
exosomes and secreted. These results suggest a hypothesis whereby BAT may export
exosomes containing miRNA-32 that activate other adipocytes and increase energy
expenditure, thereby reducing fat accumulation. Overall, administration of brown
adipocyte-derived exosomes to patients may be therapeutically beneficial for controlling
T2D if they can be harvested in sufficient quantities from cultured cells.

We hypothesize that activated human brown adipocytes grown in cell culture can be
used to isolate exosomes to determine microRNAs that may alter gene expression in an
anti-diabetic manner in distant tissues. The major goal of this project was to develop the
methods necessary to isolate exosomes and determine their microRNA content.

Methods
1)
2)
3)
4)
5)

Grow brown adipocytes in culture.
Isolate exosomes from conditioned medium.
Purify microRNA from isolated exosomes.
Make cDNA from exosomal microRNA.
Test expression of microRNAs previously shown to be present in exosomes
secreted by brown adipocytes in vivo.

Background

Results

During weight gain, periods of prolonged overeating result in fat storage in white
adipocytes, which can lead to inflammation, cellular stress, insulin resistance and
eventually T2D. Unlike the energy storage function of WAT, brown adipocytes become
metabolically activated in response to cold and burn calories by releasing energy stored
in fats to generate heat, thereby providing mammals with protection from hypothermia.
Therapeutic strategies are being sought to stimulate brown adipocytes to burn excess
calories and combat obesity.

Isolation of exosomes from brown adipocytes

A

B

Exosomes were isolated from conditioned medium (3 days conditioning) using the Total
Exosome Isolation Reagent purchased from ThermoFisher Scientific. Briefly 4 ml of
conditioned medium was spun by centrifugation at 3000xg to removed cell debris and
was then combined with 2ml of Total Exosome Isolation reagent and incubated
overnight at 4C. Exosomes were isolated by centrifugation at 10,000xg for 1 hour, and
the resulting exosome pellet was re-suspended in PBS. Flow cytometry was used to
determine the presence of exosomes after staining for exosome surface markers CD9
and CD81.

miRNA-32 expression was previously shown to necessary for activation of brown
adipocytes (Cell Rep. 2017, 19(6):1229-1246). We found that this microRNA is enriched
in exosomes (>85 fold) compared to brown adipocytes they were derived from. This
suggests that miRNA-32 may be secreted by brown adipocytes and play a role in
cellular communication, including the possibility of inducing the formation of brown
adipocytes in white adipose tissue. This could then lead to an increase in energy
expenditure and loss of body fat.

We have demonstrated that activated brown adipocytes grown in cell culture secrete
exosomes, similar to what occurs naturally after cold induction in vivo. These exosomes
express microRNAs known to be expressed in brown adipocytes, which may play a
broader role in communicating with other adipose tissue depots. Thus, cell cultures of
activated brown adipocytes may provide an easy method to determine novel microRNAs
that regulate metabolism in distant tissues. Future studies will be directed against
sequencing microRNAs from exosomes isolated from cell cultures of brown adipocytes
in our search for molecules that may regulate type 2 diabetes.

Adopted from Chen-Y, Cell
Metabolism, Vol. 25, Issue 4, 2017

https://knowledgeconnection.mainehealth.org/jmmc/vol1/iss1/16
DOI: 10.46804/2641-2225.1017

miRNA-32 is enriched in exosomes compared to brown adipocytes

Summary

C

(A) Factors contained within exosomes secreted by brown adipocytes may target and
promote anti-diabetic effects on tissues affected by type 2 diabetes, such as the liver
and white adipose tissue. (B) Exosomes carry a diverse array of signaling molecules,
including microRNAs, proteins and lipids that are transported to recipient cells and
tissues, potentially through direct homing via specific cell surface receptors. (C)
microRNAs carried by exosomes can alter gene expression in distant tissues by
binding to specific mRNA targets and silencing them.

Amplification of microRNAs from exosomes
microRNAs were extracted from exosomes isolated from brown adipocytes using the
Qiagen miRNeasy Micro Kit. microRNAs were converted to cDNA using gene specific
reverse transcriptase primers for 3 exosomal microRNA markers previously shown to be
expressed by brown adipocytes, including miRNA-92a, miRNA-99b and U6 snRNA. U6
snRNA is a non-coding small nuclear RNA commonly used as internal control to
normalize microRNA expression in cells. cDNA was amplified by qPCR using TaqMan
probe based assays for these 3 targets. These data suggest that we were able to
successfully isolate microRNAs from the exosomes of brown adipocytes.

Analysis of RNAs isolated from exosomes using the Agilent Bioanalyzer
RNA isolated from either brown adipocytes or their exosomes was analyzed with the
Agilent Bioanalyzer. Exosomes isolated from brown adipocyte exosomes showed a gel
band in the approximate range expected for miRNAs (25-200 base pairs)
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The Role of Lipid Metabolism in Multiple Myeloma
DeSchiffart, Abigail1; Masarwi, Majdi1; Reagan, Michaela R.1,2,3
1Maine Medical Center Research Institute, 2Tufts University School of Medicine, 3University of Maine Graduate
School of Biomedical Science and Engineering
INTRODUCTION
•Multiple Myeloma (MM) is the second most common type of hematological cancer, formed from a series of
oncogenetic mutations to the plasma cells of the bone marrow (1).
•Initially patients respond well to chemotherapeutic treatment, but almost all eventually develop resistance to these
treatments and experience relapse.
•Myeloma thrives in the unique and complex bone marrow microenvironment. Also, within the bone marrow are bone
marrow adipocytes (BMA) that form bone marrow adipose tissue and account for 50-70% of the total bone marrow
volume. It is believed that BMAT provides a source of energy that aids in multiple myeloma cell metastasis (2).
•Fatty acid oxidation is the process by which cells convert long chain fatty acids into NADH, FADH2, and ATP in the
mitochondria.
•CPT1 is a transport enzyme in the outer mitochondrial membrane that transports long chain fatty acids into the inner
mitochondrial space. It is the first, yet rate limiting enzyme of the carnitine system and subsequently of fatty acid
oxidation (3).
•Etomoxir (Eto) is an pharmacological irreversible inhibitor of CPT1, effectively inhibiting fatty acid oxidation.
•In other cancers, such as breast and prostate cancer, inhibiting fatty acid oxidation with the use of etomoxir has been
proven to reduce cancer cell viability and proliferation.
•Recently etomoxir has been shown to have off target effects by inhibiting complex one of the electron transport chain
at high dosages (4).

RESULTS
2. In vitro Combination Treatment of Etomoxir and Bortezomib
Eto 0 µM

Eto 5µM

Eto 12.5µM

A OPM2: Etomoxir + Bortezomib

B MM1R: Etomoxir + Bortezomib

•In addition to a potential energy source, BMAT has been shown
to increase MM’s resistance to chemotherapeutic treatments (5).
•We are examining the effect of etomoxir on different MM cell
lines and if it increases MM sensitivity to chemotherapeutic drugs.

Objective and Aims: An in vitro investigation at the effects
of inhibiting CPT1 on MM cells and to design a drug
combination treatment that effectively reduces MM cell
viability.
Figure 1 : Melone et al. Cell Death & Disease 2018. The carnitine system processes
Hypothesis: Inhibiting fatty acid oxidation in multiple
long-chain fatty acids across the mitochondrial membrane, forming acylcarnitine.
myeloma cell lines will reduce cell viability and increase Acylcarnitine then enters the mitochondrial matrix via carnitine-acylcarnitine
translocase (CACT) to undergo β-oxidation. Once in the form of Acetyl CoA, the
their sensitivity to other chemotherapeutic drugs.
fatty acid enters the Krebs cycle to produce ATP. (6)

METHODS
Cell Culture: MM1S (gfp+/luc+), MM1R (gfp+/luc+), and OPM2 (mcherry/luc+) were seeded at various densities into
clear and white 96 well plates.
Drug administration: Etomoxir (CPT1 inhibitor), Bortezomib (proteasome inhibitor), and Dexamethasone
(corticosteroid that reduces inflammation) were added at various doses 24 hours after the cells were seeded.
Bortezomib and dexamethasone are common pharmacological anti-myeloma treatments.
Cell Number: Bioluminescent imaging (BLI) was used to quantify cell viability. Luciferin (10 µL) was added to each
well and incubated for 15 minutes before reading with Glomax® Microplate Reader. BLI was read after 24, 48, 72,
and 96 hours after the drugs were administered to the cells.

1. In Vitro Measurement of Cell Viability using Bioluminescent Imaging for MM Cells
Treated with Etomoxir
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Bioluminescence read 24 hours after 500 µM etomoxir was added to the
cells. MM1S cultured at a cell density of 40,000 cells/well.

Cell viability of (A) OPM2 and (B) MM1R cells treated with etomoxir (eto) at 0 µM, 5 µM or 12.5 µM, in addition to various
doses of bortezomib (bort), specifically 0 nM, 0.25 nM, 1 nM, or 5 nM. Bioluminescence was used to measure tumor cell
number and was read 72 hours after the drugs were administered. OPM2 cells were seeded at 20,000 cells/well in 96well plates. *, p<0.05; **, p<0.01.

3. In vitro Combination Treatment of Etomoxir and Dexamethasone Co-Cultured with
MSCs
MM1S cells were directly co-cultured with mouse
mesenchymal stem cells (mMSCs) for 24 hours
before etomoxir (5µM) and dexamethasone
(0.5µM) were administered . The mMSCs were
seeded at a cell density of 7500 cells/well. The
MM1S cells were seeded at a cell density of 5000
cells/well. Statistical analysis was done using one
way ANOVA test. *, p<0.05; ****p< 0.0001.
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